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Abstract  
Nociceptive pain signals are relayed in the spinal cord as they are transmitted from 
the periphery to higher brain centers. The neuronal populations in the spinal cord that 
transmit peripheral stimuli are very heterogeneous. This has hampered the 
identification of interneuron subtypes involved in pain processing and the 
characterization of their functional connectivities. In this study, I obtained a 
transcriptomic profile of spinal cord cells specifically activated by a peripheral painful 
stimulus using the recently developed phospho-ribosome profiling technique, and 
identified Protein targeting to glycogen (Ptg) as a pain-induced gene in spinal 
astrocytes. Ptg is known to play an important role in glycogenesis. I observed elevated 
spinal cord glycogen levels in response to different painful stimuli and proposed a 
correlation between the magnitude and duration of glycogen elevation with the 
persistency of different pain models. Moreover, manipulation of Ptg expression and 
glycogen metabolism led to altered pain sensitivity. My study points toward a new 
perspective of the role of astrocytes in pain processing and a potential link between 
changes in the metabolic state and pain processing in the spinal cord.  
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Zusammenfassung  
Nozizeptische Schmerzsignale werden im Rückenmark vom peripheren Nervensystem 
an höhere Hirnzentren übertragen. Die Neuronenpopulationen im Rückenmark, die 
diese peripheren Signale übermitteln, sind heterogen was die Identifikation von 
Interneuron-Subtypen involviert in Nozizeption sowie die Charakterisierung ihres 
neuronalen Netzes erschwert. In der vorgelegten Studie habe ich mit der neu-
entwickelten „phospho-ribosome profiling“ Methode das Transkriptomprofil von 
durch periphere Schmerzsignale aktivierte Rückenmarkszellen erhalten und Ptg 
(Protein targeting to glycogen) als ein schmerzinduziertes Gen in Astrozyten 
identifiziert. Ptg spielt eine wichtige Rolle in der Glykogenese und ich konnte ein 
erhöhtes Glykogenlevel als Reaktion auf verschiedene schmerzauslösenden Stimuli 
feststellen, sowie eine Korrelation zwischen dem Ausmaß und der Dauer des erhöhten 
Glykogenlevel und der Dauer verschiedener Schmerzmodelle. Außerdem habe ich 
demonstriert, dass Manipulation von Ptg-Expression und Glykogenstoffwechsel zu 
veränderter Schmerzsensitivität führt. Daher unterstützt meine Studie eine neue 
Sichtweise auf die Rolle von Astrozyten in der Nozizeption und eine potentielle 
Verbindung zwischen Veränderungen im Stoffwechsel und der Schmerzverarbeitung 
im Rückenmark. 
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1. Introduction 
I will first introduce pain as a physiological modality as well as the pathological forms 
of pain. Next I will summarize how nociceptive signals are transduced, with an 
emphasis on the current knowledge of spinal cord neuronal circuits and glial cells 
involved in pain processing. Furthermore I will introduce a technique called phospho-
ribosome profiling that I employed in my thesis to identify spinal cord cells mediating 
pain. 
1.1 What is pain? 
First of all, pain and nociception are two different concepts. Pain is the feeling, or the 
perception of pinching, aching, stabbing, throbbing, as well as the unbearable or 
miserable sensations rising from a part of our body (Woolf & Salter, 2000). 
Nociception is the sensory process that provides the signals that trigger the conscious 
experience of pain (Bear et al., 2007).  
The uncomfortable feeling of pain indicates that damage is happening or is about 
to happen (Bear et al., 2007) and it is therefore essential for survival: pain functions as 
a very useful early warning device that alerts our body against many harmful 
environmental stimuli and triggers protective responses almost instantly (S. Hunt, P. 
& Mantyh, 2001; Julius & Basbaum, 2001). Most of the time, pain is just a nuisance 
and goes away after a while. Other times it can be devastating. When pain is too 
intense or lingers for too long, additional physical symptoms emerge: nausea, 
weakness or drowsiness. Prolonged pain may even cause emotional effects such as 
anger and depression (Bear et al., 2007).  
Pain is not homogeneous and is commonly classified into physiological and 
pathological pain (Woolf & Salter, 2000). 
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• Physiological pain  
Physiological pain is the acute, ’useful’ pain, as it triggers protective withdraw or 
escape responses. Unlike many other somatosensations, painful feelings can be 
evoked by many different stimuli. Physiological pain results from noxious stimuli 
such as (i) thermal: heat ≥ 43°C or extreme cold, (ii) mechanical: intense pressure or 
force, (iii) chemical: e.g. concentrated acid or pungent agents (Dubin & Patapoutian, 
2010). In any case, the pain goes away as the stimulus fades and the wound heals. 
Physiological pain also usually responds well to opioid or non-steroidal anti-
inflammatory drug medications. 
• Pathological pain 
There are two types of pathological pain: inflammatory pain initiated by tissue 
damage/inflammation and neuropathic pain by nervous system lesions. Both 
inflammatory and neuropathic pain are characterized by hypersensitivity at the site of 
tissue damage and in adjacent normal tissue. In both cases, pain may be elicited by 
normally non-painful stimuli (allodynia) or noxious stimuli may evoke a greater and 
more prolonged pain (hyperalgesia) (Woolf & Salter, 2000; Gangadharan & Kuner, 
2013). 
Inflammation is an adaptive response, eliciting physiological responses that 
promote wound healing. Inflammatory pain hypersensitivity usually returns to normal 
if the disease process is controlled (Medzhitov, 2008). Neuropathic pain, on the other 
hand, persists long after the initiating event has healed.  
If pain persists longer than 6 months, it is classified as chronic pain. Chronic pain 
no longer serves a biological function and is now considered no longer a symptom of 
diseases but a disease itself (Basbaum et al., 2009). Chronic pain affects up to 30% of 
the adults in the world, and there is no adequate medication to improve patients’ 
conditions (Woolf & Salter, 2000). 
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1.2 The pain pathway: peripheral nervous system 
The perception of pain involves the peripheral and the central nervous systems (PNS 
and CNS) (Damann et al., 2008). The painful stimulus is first detected in the 
periphery, by nociceptors. 
A needle pinch, like the gentle brush from the spring breeze or the rising 
temperature under the sun, is felt through our skin. In order to accurately sense all 
these stimuli, skin is heavily innervated by various somatosensory neurons. Among 
them, nociceptors sense the high threshold, pain-inducing stimuli (Bove & Swenson, 
2007; Y. Liu & Ma, 2011).  
Nociceptors, like other somatosensory neurons, are pseudo-unipolar neurons. This 
means the cell body (soma) sits in the dorsal root ganglia (DRG), with two branches 
of one single axon projecting to both the skin (peripheral) and the spinal cord 
(central). The axons of somatosensory neurons are classified as Aß-, Aδ-, or C-fibers, 
which have different degrees of myelination: the thickly myelinated Aß fibers, the 
thinly myelinated Aδ fibers, and the un-myelinated C fibers (Fig. 1A) (Bear et al., 
2007). Nociceptors comprise of either Aδ or C fibers. The Aδ nociceptive fibers detect 
the fast, sharp, precise-localized ‘fast pain’ and un-myelinated nociceptive C fibers 
convey the second wave of longer-lasting and poorly localized ‘slow pain’. The third 
type of fiber, Aß fibers, sense mechanical stimulation (Bear et al., 2007; Bove & 
Swenson, 2007). 
• Types of nociceptors  
As pain could be induced by excessive mechanical, thermal or chemical stimuli, 
nociceptors are accordingly classified by the sensory modalities that they respond to. 
However, unlike mechanoreceptors or thermoreceptors which respond only to 
mechanical or thermal stimulus, a large group of nociceptors is polymodal, i.e. they 
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respond to a combination of thermal, mechanical and/or chemical stimuli: HTM 
(high-threshold mechanical) nociceptors respond to both mechanical and chemical 
stimuli, as well as heat greater than 50°C (Basbaum et al., 2009); or CMH (C-fiber 
mechano-heat-responsive) nociceptors detect both noxious heat and excessive 
pressure (Perl, 2007). There are in addition also a group of silent nociceptors, which 
respond to none of these modalities under normal conditions, but can be activated 
when injury and inflammation occur (Schmidt et al., 1995).  
• Activation of nociceptors 
How do nociceptors ‘sense’ the noxious stimuli? Nociceptors express a unique 
repertoire of ion channels and receptors (Benarroch, 2015).  
The largest group of noxious stimulus detectors is the transient receptor potential 
(TRP) channel family, among which (i) TRPV1 is activated by capsaicin and heat, and 
(ii) TRPA1 is activated presumably by mechanical stimulus (Mickle et al., 2016) and 
has been reported as a key chemical sensor. Many pungent chemicals such as 
formalin, the most commonly used agent to assay chemical nociception in rodent, 
activate TRPA1 (Patapoutian et al., 2009). In addition to these two better studied TRP 
channels, roles of many more nociceptive TRP channels are being revealed.  
In addition to TRP channels, subtypes of voltage-gated Ca2+ and Na+ channels, K+ 
channels, acid sensing ion channels, hyperpolarization-activated cyclic nucleotide-
gated channels, TMEM16 channels, as well as 5-HT3 receptors and P2X family 
receptors have be shown to be triggered by various noxious stimuli (Benarroch, 
2015).  
The activated channels or receptors convert noxious mechanical, thermal, chemical 
stimuli into electrical activities at the peripheral terminals of nociceptors (Damann et 
al., 2008). The electrical signals then travel from the peripheral branch of the axon to 
the central branch, towards the central nervous system.  
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Figure 1: The pain pathway  
1A: The pain pathway: primary sensory neurons innervate the skin via various types of sensory 
afferents: thickly myelinated Aß fibers sense mechanical stimuli, thinly myelinated Aδ fibers detect 
pain and temperature, and un-myelinated C fibers are responsible for pain, temperature and itch. The 
fibers project first to spinal cord in a lamina-specific fashion and then further to the brain. Adapted 
from (Lumpkin & Caterina, 2007).  
1B: Connections between primary afferents and the spinal cord. Aß fibers (orange) project to deeper 
laminae III and IV, Aδ fibers (purple) project to both outer lamina II and lamina V, peptidergic C fibers 
(red) project to superficial lamina I, and non-peptidergic C fibers (blue) project to inner lamina II. 
Adapted from (Basbaum et al., 2009). 
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1.3 The pain pathway: central nervous system 
Of the central nervous system (CNS), spinal cord is the first relay station of peripheral 
stimuli and the processed information then enters the higher brain center. As I aim to 
gain more knowledge of pain precessing at the spinal cord through my project, I will 
put an emphasis on summarizing the current knowledge on spinal cells (neurons and 
glia) involved in pain processing. 
1.3.1 Spinal cord neurons in pain processing  
The spinal cord is the first relay station in the processing of noxious stimuli from the 
periphery. Axons of different somatosensory neurons project into the spinal cord 
dorsal horn, where nociceptive information is integrated along with other somatic 
sensory information.  
The central branches of the somatosensory neuron axons enter the dorsal horn of 
the spinal cord and synapse on the dorsal horn cells (Bear et al., 2007). Information 
processing in the dorsal spinal cord is segregated: different axon fibers project to 
different layers of the dorsal spinal cord (Fig. 1B). Nociceptive Aδ- and C-fibers 
project to the superficial dorsal layers (laminae I and II) while the non-nociceptive 
Aδ- and mechanoreceptive Aß- fibers project to the deeper dorsal layers (laminae III-
V) (Basbaum et al., 2009). The dorsal horn neurons are comprised of a large variety of 
interneurons (IN) and a smaller group of projection neurons (PN) (Todd, 2010).  
Interneurons are named so because their axons remain in the spinal cord and 
arborize locally. There are two main types of interneurons: (i) excitatory interneurons, 
which utilize glutamate as their neurotransmitters, i.e. glutamatergic; and (ii) 
inhibitory interneurons, which use gamma-aminobutyric acid (GABA) alone or a 
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combination of GABA and glycine as their main neurotransmitters. Interneurons are 
also classified by their dendritic morphologies: islet, central, vertical and radial (Grudt 
& Perl, 2002). This morphological classification however remains a very crude one as 
morphological features do not necessarily correlate with molecular and functional 
diversities, which are only starting to be revealed. 
Excitatory interneurons have been shown to be diverse in terms of marker 
expression and the functional properties of some of these different neuron types have 
already been analyzed. Calretinin (Calb2)-expressing neurons for instance spread over 
laminae I and II, and are suggested to transmit only light acute mechanical pain (Duan 
et al., 2014b). Protein kinase C gamma (Pkc-γ)-expressing neurons are expressed in 
lamina I and inner lamina II, and has been proposed to mediate mechanical allodynia 
(Koch et al., 2017). Somatostatin (Som)-expressing neurons are one of the most 
abundant excitatory interneurons (~60%) (Gutierrez-Mecinas et al., 2016; Todd, 2017) 
and are found from laminae I to III. These Som-expressing neurons have been shown 
to be involved in acute mechanical pain. Ablation of Som-expressing neurons leads to 
the loss of both static and dynamic allodynia upon inflammatory pain, while transient 
activation of Som-expressing neurons results in immediate nocifensive responses 
(Duan et al., 2014b; Christensen et al., 2016). MafA-expressing neurons are localized 
mainly in laminae III and IV (Del Barrio et al., 2013) but also scatter into laminae I 
and II (Appendix). Altered mechanical pain threshold has been observed in MafA-
knock-out mice after inducing chronic pain (Appendix). Cholecystokinin (Cck)-
expressing neurons are localized mainly in the deeper dorsal horn. The ablation of 
Cck-expressing neurons leads to a transient insensitivity to noxious cold (Haueter, 
2016).  
Subgroups of inhibitory interneurons have been identified and their functions in 
pain processing studied. Dynorphin (Dyn)-expressing neurons are enriched in 
superficial laminae (Xu et al., 2008). Spinal Dyn-ablated mice are reported to show 
spontaneous development of both static and dynamic mechanical allodynia (Duan et 
al., 2014b). Glycine transporter 2 (Glyt2)-expressing neurons spread through the 
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deeper dorsal horn laminae III-V (Zeilhofer et al., 2012). Ablation or silencing of 
spinal Glyt2-expressing neurons results in an abnormally exaggerated sensitivity to 
mechanical, heat and cold stimuli and the development of spontaneous pain. 
Conversely, activation of the same neurons alleviated neuropathic hyperalgesia 
(Foster et al., 2015).  
Projection neurons are mainly located in lamina I but are also found scattered 
through laminae II–VI. The projection neurons project to the brain. Although the brain 
areas to which their ascending axons project to have been largely mapped, the 
heterogeneity of the lamina I projection neurons remains an obstacle to categorize 
them into discrete groups. The Neurokinin 1 receptor (Nk1r) is expressed by many 
lamina I projection neurons (~80%) and ablation of Nk1r-expressing neurons prevents 
the development of both mechanical and thermal hyperalgesia (Mantyh et al., 1997; 
Todd, 2010; Weisshaar & Winkelstein, 2014).  
In addition of lamina specific markers, combinations of markers have also been 
reported to define subpopulations of spinal cord neurons, such as in the study by Del 
Barrio and colleagues (Del Barrio et al., 2013), in which a set of nine transcription 
factors (Fig.2A) was used to define nine different inhibitory and excitatory 
interneuron populations. These recent studies on dorsal horn lamina-specific neuron 
populations and their roles in pain processing have resulted in a dramatic 
improvement in our understanding of pain processing at the spinal level (Todd, 2017).  
• Spinal cord pain circuit  
Spinal cord neurons are not only extremely heterogenous themselves, they also form 
sophisticated circuits in pain processing. Ronald Melzack and Patrick Wall proposed 
the gate theory of pain in the 1960s to explain the interaction between the excitatory 
and inhibitory circuits in spinal cord pain processing (Ronald & Patrick, 1965). 
The gate theory of pain hypothesizes that nociceptive transmission neurons (TN) 
of the spinal dorsal horn are activated not only by high-threshold Aδ/C nociceptors, 
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but also by low-threshold Aß mechanoreceptors. However, this input from Aß 
mechanoreceptors is gated by feed-forward activation of inhibitory interneurons (iIN) 
(Fig.2B). Therefore, (i) when there is only high-threshold painful stimulus, the 
nociceptive TN is activated. In addition, as iIN is inhibited by painful stimulus, 
maximal nociceptive signals ascend to the brain. (ii) When there is only low-threshold 
mechanical stimulus, activation of iIN prevents low-threshold mechanical stimulus 
from activating the pain transmitting TN. (iii) If there are simultaneous inputs from 
high-threshold Aδ/C nociceptors and low-threshold Aß mechanoreceptors, activated 
iIN suppresses the activity of TN, thus reducing the nociceptive signals rising to the 
brain. This is why it feels good to rub the skin around a bruise. To sum this up, spinal 
nociceptive transmission neurons are gated by inhibitory interneurons through feed-
forward inhibition (Duan et al., 2014b; Peirs et al., 2015).  
Since the proposal of the gate theory of pain, numerous studies have tried to test 
the key argument of the theory. This theory first of all correctly predicted that 
disinhibition (the injured state) could be a reason for the development of mechanical 
allodynia, i.e. pain by innocuous mechanical stimuli (Zeilhofer et al., 2012; Prescott et 
al., 2014). And several electrophysiological studies have since revealed the existence 
of a circuit linking input to lamina III by mechanosensitive Aß fibers with lamina I 
projection neurons (Torsney & MacDermott, 2006; Takazawa & MacDermott, 2010). 
However, the precise make up of the spinal cord pain circuit is only starting to be 
discovered (Duan et al., 2014a). Below I summarize the main recent findings in spinal 
pain circuits: 
Lamina III glycinergic (Glyt2+) neurons are believed to represent one group of the 
above-described iIN. They are inhibitory interneurons and are innervated by Aß 
fibers. Ablation of GlyT2+ neurons leads to hyperalgesia, while activation of them 
effectively alleviates neuropathic pain, indicating a role of Glyt2+ neurons in gating 
pain. Paired patch-clamp recordings showed that inner lamina II Pkc-γ+ interneurons 
are gated by these glycinergic inhibitory interneurons through feed-forward inhibition. 
In the original gate theory of pain, TN was proposed to comprise solely of projection 
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neurons, but this study suggests that TNs can also be lamina II interneurons (Lu et al., 
2013; Foster et al., 2015). 
Som+ excitatory interneurons and Dyn+ inhibitory interneurons are another pair 
identified as the TN and IN in the gate theory, respectively. Som+ neurons receive both 
low-threshold Aß mechanical and high-threshold Aδ/C nociceptive inputs. Upon 
ablation of dorsal spinal cord Dyn+ neurons, Som+ excitatory neurons are activated by 
low-threshold mechanical stimulus. Dyn+ inhibitory neurons thus act to prevent low-
threshold mechanical stimulus from activating Som+ excitatory neurons, i.e. Dyn+ 
inhibitory neurons gate Som+ excitatory neurons (Duan et al., 2014b). 
Two additional IN groups have been identified: (i) lamina III inhibitory 
interneurons expressing parvalbumin (Pv+) gate Pkc-γ+ excitatory interneurons. PV+ 
neurons have been proposed to modulate hypersensitivity especially in inflammatory 
and neuropathic pain (Petitjean et al., 2015); and (ii) lamina III-V inhibitory 
interneurons with neonatal expression of receptor tyrosine kinase (Ret+) gate both 
Som+ and Pkc-γ+ excitatory interneurons. These transient Ret expressing neurons are 
involved in modulating mechanical pain as well as inflammatory and neuropathic pain 
(Cui et al., 2016; Koch et al., 2017).  
In a subsequent study, a lamina III to I circuit involved in persistent mechanical 
pain (neuropathic and inflammatory) transmission was mapped (Peirs et al., 2015). A 
group of Lamina III excitatory interneurons with transient postnatal Vglut3 expression 
receives Aß input and synapses to the more dorsal lamina II excitatory interneurons 
expressing Pkc-γ and Calb2, which act to refine the excitability of the circuit. The 
lamina II vertical cells then integrate these signals and send an output to the lamina I 
nociceptive Nk1r+ projection neurons (Peirs et al., 2015). Dorsal horn ablation of this 
transient Vlgut3+ interneuron population reduces the brush-evoked dynamic 
mechanical hypersensitivity, but not the filament-evoked punctate hypersensitivity 
(Cheng et al., 2017). 
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To briefly summarize the above-mentioned spinal cord pain circuits, with a focus 
on mechanical pain processing, TN (Som+ /Pkc-γ+/Calb2+ neurons) are gated via feed-
forward activation of IN (GlyT2+/Dyn+/PV+/Ret+ neurons), preventing the activation 
of nociceptive TN by low-threshold mechanical inputs. The exact interaction and 
segregation of the four IN populations are not yet clear (Duan et al., 2017). And under 
persistent mechanical pain, transient Vlgut3+ interneurons are activated to convey 
mechanical hyper-sensitivities. Despite the tremendous progress, we still have many 
gaps to fill for a generally accepted scheme that covers all the spinal dorsal horn 
neurons and their circuits. 
1.3.2 Spinal cord glia in pain processing  
The nervous systems mainly consist of two cell types, the neurons and the glia. The 
role of neurons, primary or spinal, has been the main focus of pain research. For quite 
a long time, the predominant thinking in the pain field was that pain was purely a 
matter of miscommunication between neurons (Miller, 2005). There has been 
emerging evidence suggesting the involvement of glia in pain hypersensitivity. 
Originally considered as supporting cells to neurons, glial cells have now been shown 
to actively communicate with neurons and contribute to many aspects of neuronal 
functions including pain processing (Kohno, 2010; Chiang et al., 2012). Glial cells 
make up over 70% of the CNS cells and are divided into astrocytes, oligodendrocytes 
and microglia (Fig.2C).  
Astrocytes are named after their star shape. They are the most abundant glial cell 
type, making up 40% to 50% of all glia cells (Aldskogius & Kozlova, 1998). There 
are two main categories of astrocytes: (i) Protoplasmic astrocytes in the gray matter 
with a morphology of several stem branches and many finely branching processes in a 
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uniform globoid distribution, and (ii) Fibrous astrocytes in white matter and have 
many long fiber-like processes (Fiacco et al., 2009). Astrocytes are known to fulfill 
many functions including the maintenance of the homeostasis, metabolic support for 
neurons, and maintenance of the blood-brain barrier (Sofroniew & Vinters, 2010). 
Microglia are the resident macrophages in the CNS, as they act as the first and main 
form of active immune defense. In resting states, microglia are ramified with thin 
branches. Once reactive i.e. activated, they become amoeboid with thick and short 
branches (Ru-Rong Ji & Wen, 2006).  
Oligodendrocytes are the myelinating cells in the CNS. Their main functions are to 
provide support and insulate CNS axons with the myelin sheath.  
• Spinal astrocytes and microglia in pain processing 
Astrocytes are the only glial cells to form networks with themselves and are closely 
associated with neurons. Each astrocyte is estimated to be in contact with 300 to 600 
neuronal dendrites (Halassa et al., 2007). This close contact makes astrocytes capable 
of responding to neurotransmitters. In addition, upon peripheral tissue damage or 
inflammation, spinal dorsal horn astrocytes become reactive and release 
gliotransmitters, which in turn regulate nociceptive neuronal activities (Chiang et al., 
2012). Spinal astrocytes undergo biochemical, translational, transcriptional, and 
morphological changes when they become reactive. Some changes occur within 
minutes after receiving peripheral nociceptive stimuli, such as increasing intracellular 
Ca+ level and phosphorylation of signaling molecules, e.g. p-JNK. Translational 
modifications and transcriptional regulations happen after tens of minutes to one hour. 
Morphological change such as astrocyte hypertrophy may occur only hours or even 
days later (Gao & Ji, 2010).   
Microglia have been shown to be the quickest responder to peripheral nerve injury 
(Kreutzberg, 1996). In most cases, microglial reaction precedes astrocytic reaction and 
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likely leads to astrocyte reaction, though the activity of the two are not always linked 
(Hald et al., 2009; Gao & Ji, 2010). 
Activation of spinal astrocytes and microglia has been reported in many pain models: 
Inflammatory pain: 
Astrocyte activation was found in formalin-induced pain, preceding microglia 
activation. It is suggested that astrocytes modulate the formalin-induced hyperalgesia 
via astrocytic-neuronal heterotypic gap junctions (M. Qin et al., 2006). In complete 
freud’s adjuvant (CFA)-induced pain, gene expression studies showed elevated 
microglial markers through all phases (acute, subacute and chronic) of the 
inflammation. While on the contrary, up-regulation of astrocytic markers was 
observed only during the subacute and chronic phases (Raghavendra et al., 2004). 
Upon zymosan-induced pain, blocking glial metabolism resulted in a marked, but 
reversible, attenuation of the persistent thermal and mechanical hyperalgesia (Meller 
et al., 1994). 
Neuropathic pain:  
Astrocyte activation has been shown in various neuropathic pain models, e.g. spared 
nerve injury (SNI) and chronic constriction injury (CCI). It is suggested that 
astrocytes are involved in the maintenance phase of chronic neuropathic pain, rather 
than during the onset (Garrison et al., 1991; Tanga et al., 2006). Microglia, on the 
other hand, are quickly activated after peripheral nerve injury and are involved in both 
the onset and the maintain of chronic neuropathic pain (Hains & Waxman, 2006). 
Although the involvement of astrocytes and microglia in pain processing is widely 
proven, and we are starting to unravel the modulators and pathways of glia-neuron 
interaction (Guan et al., 2016; Lim et al., 2017), there remains many missing links in 
the mechanism of glia-neuron interaction in pain processing to be discovered. 
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Figure 2: Spinal cord pain processing 
2A: Lamina distribution of few known dorsal spinal cord-specific genes. 
2B: Gate theory of pain. Spinal transmission neurons (TN) are gated by inhibitory interneurons (iIN) 
through feed-forward inhibition: TN is activated by both nociceptive Aδ/C fibers and mechanosensitive 
Aß fibers, and inhibited by the neighboring iIN. iIN is activated by mechanosensitive Aß fibers and 
inhibited by nociceptive Aδ/C fibers. Therefore, when there is only nociceptive signal, iIN is silent and 
maximal signal is sent to the brain from TN; when there is a combination of nociceptive and 
mechanical stimuli, iIN is activated, which in turn reduces the signal sent by TN. Adapted from (Duan 
et al., 2014a).  
2C: Glial cells are in vicinity of neurons and hold important functions in the central nerve system 
(CNS) including spinal cord, shown here. Astrocytes are the most abundant of the glial cells and are in 
closest communication with neurons, serving diverse functions from maintaining homeostasis to 
metabolic support. Microglia are the resident macrophage of CNS and oligodendrocytes are the 
myelinating cells in the CNS. Adapted from (Ru-Rong. Ji et al., 2016). 
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Figure 3:  The spinothalamic pathway  
The spinothalamic pathway. Spinal cord neurons, which receive nociceptive signals from primary Aδ/C 
fibers, decussate immediately and ascend to thalamus without synapsing. The thalamic neurons then 
project to cerebral cortex, where nociceptive signals are translated to the perception of pain. Adapted 
from (Bear et al., 2007). 
1.3.3 Pain processing at higher brain centers 
Nociceptive information is conveyed from the spinal cord to the brain via the 
spinothalamic pathway (Fig.3). The axons of spinal projection neurons decussate 
immediately to the opposite side of the spinal cord, i.e. nociceptive information 
travels contra-laterally, and ascend through the spinothalamic tract running along the 
ventral surface of the spinal cord. As the name spinothalamic indicates, the 
spinothalamic fibers project up the spinal cord and go through first medulla, pons and 
midbrain without synapsing, until they reach the thalamus. From the thalamus, 
nociceptive information is projected to various areas of the cerebral cortex (Bear et 
al., 2007; Segerdahl et al., 2015). Activation of nociceptors can lead to the conscious 
experience of pain. However, pain can be felt without activity in nociceptors i.e. the 
brain may experience pain without receiving any input from peripheral nociceptors 
(Bear et al., 2007; Dubin & Patapoutian, 2010).  
Characterization of both the brain regions that are involved in pain processing and 
the peripheral nociceptors has been the main focus of pain research. While research in 
the last decade has tremendously enriched our knowledge about spinal cord pain 
processing, we still have many gaps to fill. 
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Figure 4: Ribosome phosphorylation and phospho-ribosome profiling 
4A: Neurotransmitters and modulators activate a set of signaling pathways. Ribosomal protein S6 is 
downstream of these pathways and is phosphorylated in an activity-dependent fashion. Adapted from 
(Knight et al., 2012). 
4B: Phospho-ribosome profiling experiment scheme: Mice are administrated a peripheral painful 
stimulus. Upon receiving the nociceptive signals, spinal cord pain processing cells are activated and 
subsequently show enhanced S6 phosphorylation (pS6). pS6 immunoprecipitation (IP) is performed to 
enrich for the phospho-ribosome bound mRNA from these activated cells. Subsequent transcriptome 
analysis of the collected mRNA reveals the molecular profiles of the activated cells.  
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1.4 Phospho-ribosome profiling 
In spinal pain processing research, studies of neurons have been mainly based on 
electrophysiology and the manipulation of cell populations with known distinct dorsal 
spinal cord expression patterns (see section 1.3). Till date, there remains gaps in our 
knowledge about the molecular and functional diversity of spinal cord cells.  
During my PhD, I aimed to expand our understanding of spinal pain processing from 
an activity-dependent angle i.e. to look for the cell populations responsible for a 
certain defined nociceptive response, rather than the ‘phenotypical and behavioral 
characterization of a defined cell population’ approach that has been employed in the 
aforementioned studies.  
A recently developed technique by Knight and colleagues allows the transcriptomic 
analysis of cells that are specifically activated by certain stimulus (Knight et al., 
2012). This technique, termed phospho-ribosome profiling, takes advantage of the 
activity-dependent phosphorylation process of the ribosomal protein S6 (pS6), which 
is downstream of PI3-K/mTOR, MAPK and PKA signaling pathways. These same 
pathways lead to the expression of known activity-dependent genes such as c-Fos 
(Fig.4A). Antibodies against the phosphorylated S6 episode can therefore be used to 
capture ribosomes from cells that have been activated by a given stimulus. Using pS6 
immunoprecipitation, the mRNA bound to these ribosomes can be isolated. Thereby, 
mRNA from the activated cells is selectively enriched. Population markers or stimuli-
specific gene inductions can subsequently be revealed by mRNA sequencing. 
Phospho-ribosome capturing has been successfully employed to identify 
hypothalamic neuronal populations activated by salt challenge or fasting and stimuli-
specific odorant receptor expressions in olfactory neurons (Knight et al., 2012; Jiang 
et al., 2015). I reasoned that this technique would provide me a link between functions 
and molecular profiles of the spinal cells activated during pain processing. 
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1.5 Objectives 
Despite the tremendous progress that has been achieved in the recent years, there are 
still many interesting questions in the pain field, especially (1) what stable markers 
are there that distinguish spinal cell populations specifically activated during (chronic) 
pain processing? and what are the exact mechanism of these cells in the spinal pain 
circuits? (2) what are the genetic programs that are specifically altered in spinal cells 
activated by peripheral painful stimuli? which particular cell types contribute to these 
transcriptional changes and how might the altered gene expression affect structural 
changes that are involved in pain processing and the development of chronic pain 
states? 
To address these questions, I employed the phospho-ribosome profiling technique 
for the advantages of (i) the phosphorylation of ribosome is activity dependent, and 
(ii) the mRNA bound to the phosphorylated ribosomes carry the molecular profiles of 
the activated cells. I would obtain transcriptomic profile of spinal cells specifically 
activated by peripheral pain.  
As we already know, pain is very heterogeneous, and so are spinal cell populations. 
While tremendous progress has been made in deciphering the molecules and 
mechanisms that mediate the activities of peripheral nociceptors, we are only at the 
start to understand the interneurons and projection neurons in the dorsal spinal cord, 
let alone the recently emerging spinal glial cells.  
With the help of resources such as the Allen Brain Atlas, we can now look up the 
expression patterns of numerous genes in the nervous systems, including spinal cord. 
As previously summarized, progress has been made in investigating the roles of 
certain spinal dorsal horn neuron populations in pain processing. These studies were 
mainly performed by selectively and specifically ablating or activating spinal neurons 
which express certain marker genes, followed by pain-related behavioral 
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characterization. In my study, I aim to extend our understanding of spinal pain 
processing from a different angle, to look for genes which mark spinal cell population 
and genes whose expressions are specifically altered in spinal cells activated by 
peripheral painful stimuli.   
I took formalin-induced acute pain as the pain model to start with. I first 
established and optimized the phospho-ribosome profiling protocol in spinal cord 
tissue, as the original study by Knight and colleagues was performed in hippocampus 
and using different stimuli (Knight et al., 2012). After the modifications were 
finalized, I performed pS6 immunoprecipitation and the subsequent deep sequencing 
of the collected phospho-ribosome-bound mRNA (experiment scheme illustrated in 
Fig.4B). Following sequencing data analysis, I verified a list of selected candidates by 
means of qPCR and in situ hybridization staining. I then focused my study on one of 
the verified candidates, Protein targeting to glycogen (Ptg), and studied its 
involvement in spinal pain processing.  
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2. Result 
2.1 Establishing spinal cord phospho-ribosome profiling 
In my project, I aimed to use phospho-ribosome profiling to identify stable markers of 
spinal cells and specifically altered gene expressions involved in pain processing. To 
do this, I first characterized the activity-dependent phosphorylation of the ribosomal 
subunit S6 (pS6) in the spinal cord in the context of painful stimulation of the hind 
paw.  
2.1.1 Comparison of S6 phosphorylation with c-Fos expression in the dorsal 
spinal cord upon formalin-induced acute pain 
The expression of the immediate early gene c-Fos has classically been used as a 
marker for neuronal activity (S. P. Hunt et al., 1987; Morgan & Curran, 1991). c-Fos 
was also shown to be induced in dorsal spinal cord neurons upon formalin-induced 
acute pain (Harris, 1998). Therefore, I examined c-Fos mRNA expression in the 
dorsal spinal cord upon formalin-induced acute pain and compared it to S6 
phosphorylation (pS6) in order to confirm the validity of pS6 as an activity marker in 
the spinal cord. I first characterized the rostral-caudal expression pattern of c-Fos in 
the spinal cord after formalin injection into the hind paw. Lumbar spinal cord tissue 
was collected 2 hours after unilateral intraplantar formalin injection into the hind paw 
and c-Fos mRNA was visualized by in situ hybridization (Fig.5A). Strong c-Fos 
mRNA was detected through the spinal dorsal horn ipsilateral to the formalin 
injection, while weak expression was also observed in the deep layers (laminae III and 
deeper) of the contralateral side i.e. c-Fos mRNA is strongly and specifically induced 
in ipsilateral (stimulated) laminae I-III.  
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The somatosensory inputs from the hind limb are processed at lumbar spinal cord 
levels. Rostral-caudally, there are 6 sections of lumbar cord (L1 being the most rostral 
section and L6 the most caudal) (Bear et al., 2007). When I examined the rostro-
caudal distribution of c-Fos upon formalin injection in the hind paw, I observed c-Fos 
mRNA expression through out L2 to 6, peaking at L3 and L4 .  
Next, I performed immunofluorescent stainings of c-FOS and pS6 on spinal cord 
cross sections using the formalin-induced acute pain model. Since both c-FOS and 
pS6 antibodies available to me at the time were raised in rabbits, co-staining of the 
two was unfortunately not possible. Nevertheless, comparing their protein expression 
on consecutive sections revealed similar patterns in superficial laminae I to III, 
marked by the solid white line (Fig.5B). Although pS6 was widely distributed in the 
deeper dorsal layer and ventral spinal cord, its expression in the superficial dorsal 
horn was specific to the formalin stimulation and therefore could be used as an 
activity marker for the spinal cells activated by formalin-induced acute pain. 
2.1.2 Spatial distribution and time kinetics of spinal pS6 
2.1.2.1 Spatial distribution 
Both c-Fos and pS6 were specifically induced in the superficial dorsal horn. I 
therefore asked whether they would also share the same rostro-caudal distribution. 
Hence, I performed whole mount immunofluorescent staining to visualize pS6 across 
the lumbar spinal cord. Z-stack images were taken through the superficial dorsal horn 
and a maximal projection image of the pS6 expression profile was generated (Fig.5C). 
Ipsilateral specific pS6 expression was observed through L3 to L6, with maximal 
intensity at L4. This spatial distribution was confirmed by stainings of spinal cord 
cross-sections of L3 to 6 (Fig.5D).  
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Figure 5: pS6 marks spinal cord cells activated by peripheral painful stimulus  
5A:  c-Fos mRNA expression (in situ hybridization) in dorsal spinal cord 2 hours after intraplantar 
formalin injection. The expression spread through lumbar section L2 to 6 and was specific to the 
ipsilateral (side of injection) spinal cord in superficial laminae I-III. 
5B: Expression patterns of c-FOS (up, immunofluorescence) and pS6 (down, immunofluorescence) at 
L4 spinal cord, 2 hours after intraplantar formalin injection. Similarly as c-FOS, pS6 showed specific 
expression in the superficial laminae I-III (above the solid line). In deeper dorsal and ventral horns, pS6 
expression were found in both ipsilateral and contralateral sides.  
5C: Spatial distribution of pS6 (whole mount immunofluorescence) in L3 to 6 spinal cord, 2 hours after 
intraplantar formalin injection. Maximal projection image of z-stack images of the dorsal horn is shown 
here. 
5D: pS6 expression (immunofluorescence) on lumbar spinal cord cross sections. L3 and 4 showed 
maximal pS6 expression at the superficial dorsal horn, corresponding to the whole mount staining 
shown in 5C. 
5E: Time course of pS6 expression (immunofluorescence) in superficial dorsal horn. pS6 expression 
increased from 0.5 to 1 hour after formalin injection. Between 1 to 2 hours after injection, similar 
number of pS6 expression cells and similar signal intensity were observed. The expression declined 
slightly at 2.5 hours. 
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2.1.2.2 Time course 
So far I could show that pS6 is expressed 2 hours after formalin injection, but is this 
the time when pS6 expression reaches its peak, or exhibits the best ipsi- to contra-
lateral contrast? It has previously been shown that c-Fos expression is induced within 
5 minutes of neuronal activation and reaches its peak within 20 minutes (Harris, 
1998); In order to determine when pS6 expression would reach its peak, I checked 
pS6 levels at different time points after stimulation (Fig.5E). In the area of interest i.e. 
the superficial laminae I-III, I found an increased pS6 expression from 0.5 to 1 hour 
after stimulation. The pS6 expression did not significantly change between 1 and 2 
hours after formalin injection and showed a small decline after 2.5 hours. As I am 
interested in finding stable markers, I reasoned that although pS6 expression levels 
did not significantly change between 1 and 2 hours after stimulation, the 2-hour time 
point might provide me a more stabilized transcriptome. Therefore, the time point of 2 
hours post formalin injection was used in following experiments. 
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Figure 6: Optimization of pS6 immunoprecipitation in spinal cord tissue 
6A: Testing antibodies (Cell Signaling polyclonal antibody #2215, Cell Signaling monoclonal antibody 
#5364 and Invitrogen polyclonal antibody #44923G) for pS6 immunoprecipitation. Lysate (Ly), the 
three supernatants (SN) after antibody incubation and the respective immunoprecipitation eluates (IP) 
were loaded on one western blot gel. All three tested antibodies reduced pS6 amount in the supernatant 
after immunoprecipitation (SN) while #5364 showed best enrichment (IP).   
6B: Testing antibody incubation time for pS6 immunoprecipitation: 2 hours (up) vs. 10 minutes 
(down). Both incubation lengths reduced pS6 in SN and showed increased pS6 level in IP, while IgG 
control did not bind any pS6. 
6C: qPCR testing of mRNA collected by 2-hour or 10-minute pS6 immunoprecipitation. Longer 
incubation time yielded 17 times (∆Cq=4.085) more house keeping gene Rpl27 than the shorter 
incubation time, while 2 times more FosB was enriched with the shorter 10-minute IP (normalized to 
house keeping gene Rpl27, N=2). 
6D: pS6 immunoprecipitation of ipsilateral (+) and contralateral (-) dorsal spinal cord. A 10-minute 
antibody incubation was performed. pS6 was detected in both ipsi- and contra-lateral lysates, reduced 
in SN and enriched in IP. IgG control did not bind any pS6.  
6E: qPCR test of pS6-bound mRNA collected in the immunoprecipitation from 6D. Among the genes 
tested, Nk1r showed a stable enrichment (fc 2.439±0.166). Som and FosB also showed enrichment but 
greater variance among samples (N=3). 
6F: qPCR test of the cDNA library before sequencing. Nk1r showed a slight enrichment while c-Fos 
and Fos-B showed significant and consistent enrichment (N=3). 
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2.2 Enrichment of phospho-ribosomes from pain-activated spinal 
cells 
2.2.1 Optimization of pS6 immunoprecipitation protocol 
I showed by immunofluorescent staining that pS6 expression (1) specifically marks 
activated cells in superficial dorsal horn, and (2) is at its peak 2 hours after peripheral 
formalin injection. I next moved on to test conditions for pS6 immunoprecipitation 
(IP). 
2.2.1.1 Comparison of different pS6 antibodies 
The initial pS6 immunofluorescent stainings in section 2.1 were performed using the 
Cell Signaling polyclonal antibody #2215, which is the antibody used by Knight and 
colleagues in their original phospho-ribosome profiling study (Knight et al., 2012). I 
included two more antibodies for IP testing: Cell Signaling monoclonal antibody 
#5364 and Invitrogen polyclonal antibody #44923G. I performed three immuno-
precipitations in parallel using the three antibodies, respectively with the same spinal 
cord tissue lysate (lumbar sections L2-6, ipsilateral to formalin injection). I started 
with the IP condition of 2-hour antibody incubation at 4˚C.  
I loaded the tissue lysate, three supernatants (lysates after IP), and the respective IP 
eluates on one western blot gel to check for changes in pS6 level. The blot was 
incubated with antibody #2215 (Fig.6A, the antibody labels refer to the one used in 
IP). Comparing to pS6 level in the lysate, all three antibodies were able to decrease 
pS6 levels, as shown by the weaker bands in supernatants; while antibody #5364 
showed the most enrichment of pS6. The pS6 bands of the three supernatants may be 
too weak to detect their differences, the bands in IP nevertheless reflect the amount of 
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pS6 each antibodies enriched. Antibody #5364 was used for further IP experiments 
and western blot detections. 
2.2.1.2 Comparing pS6 IP incubation time 
Knight and colleagues reported that immunoprecipitations performed for more than 
10-minutes at room temperature (RT) increased unspecific binding (Knight et al., 
2012). Therefore, I compared 2-hour (4˚C) and 10-minute (RT) IP in parallel to 
compare both the quantity of pS6 enriched, as well as the quantity and quality of 
collected ribosome-bound mRNA. Again I ran western blots to determine the pS6 
levels in the lysate, supernatants and eluates of the two different IPs. Both 2-hour and 
10-minute incubation decreased pS6 levels in the supernatant, and enriched for pS6 in 
the eluates (Fig.6B). The 2-hour incubation reduced more pS6 from supernatants, but 
the two incubation lengths resulted in similar pS6 amounts in the eluates. This 
suggests that there are no significant difference in the amount of pS6 enriched by IP 
incubation of different lengths. In addition, although IgG control incubation slightly 
reduced pS6 in supernatants in both conditions, no pS6 was pulled down, indicating 
the enrichment is specific. Therefore I went forward to examine the mRNA collected 
by the two IP durations.  
Freshly transcribed mRNA is pulled down together with phospho-ribosomes, and they 
bear the molecular identities of those activated cells to whom the phospho-ribosome 
belong to. As pS6 is the mean to enrich for mRNA from activated cells and it is the 
mRNA collected that I am interested in, I then performed qPCR experiments with 
eluates from both IPs to determine the amount and to check the quality of the mRNA 
collected (Fig.6C, left). The housekeeping gene Rpl27, a ribosome subunit encoding 
gene, was used as an indication of the amount of total mRNA collected. The 2-hour 
incubation resulted in more than 17 times more of Rpl27 than the 10-minute IP, 
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suggesting that more mRNA was collected with longer incubation times. However, if 
taking Rpl27 as the indicator for total mRNA amount, the expression of FosB, an 
immediate early gene of the Fos family, is two times higher in the 10-minute IP 
compared to the 2-hour IP (Fig.6C, right). These data indicate that although the 2-hour 
incubation collected more mRNAs, the 10-minute IP achieved a higher enrichment of 
mRNA from activated cells. Hence, I decided to use the 10-minute room temperature 
immunoprecipitation in the future. 
2.2.2 Immunoprecipitation of phospho-ribosomes from the spinal cord after 
formalin-induced acute pain 
After testing different conditions, I finalized a pS6 immunoprecipitation protocol, 
namely a 10-minute room temperature incubation with Cell signaling monoclonal 
antibody #5364. As previously shown in section 2.1, I could show specific pS6 
expression in superficial dorsal horn of lumbar spinal cord L3-6, 2 hours after 
formalin injection. I adopted a dissection scheme to separate superficial dorsal horn 
from the rest of the spinal cord to further enhance the signal-to-noice ratio, as I have 
observed pS6 expression also in ventral spinal cord (FIg.5D). With this dissection 
scheme, I was able to isolate laminae I-III dorsal horn spinal cord from lumbar section 
L2-6, ipsilateral and contralateral to formalin injection respectively, as the input for 
pS6 immunoprecipitation.  
Next, I performed pS6 immunoprecipitation with the collected tissue lysates using the 
above protocol. Westernblotting of the samples showed that, first of all, pS6 was 
detected in both ipsi- and contra-lateral lysates. Although previous immunofluorescent 
staining had shown clear ipsi- to contra-lateral contrast of pS6 expression in laminae 
I-III, here I observed pS6 signals from both sides on the western blot, suggesting  that 
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either deeper dorsal lamina layers (where contralateral pS6 expression was also 
found) were also collected, or the anti-pS6 antibody showed different specificity in 
recognizing pS6 on tissue section as in lysates. Nonetheless, consistent with results 
shown above, pS6 levels were reduced in the post-IP supernatants and an enrichment 
of pS6 was detected in the IP eluates on both sides. The IgG control IPs did not pull 
down pS6, suggesting there was no unspecific binding of the pS6 to the magnetic 
beads used in the experiment (Fig.6D). Next, I went to analyze the mRNA that were 
collected by pS6 IP. 
2.2.3 qPCR validations of pre-sequencing samples 
To test the molecular information that the obtained mRNA encode and whether there 
was enrichment of transcripts from activated cells, I performed qPCR on a subset of 
transcripts known to mark subpopulations of neurons involved in spinal pain 
processing: the excitatory interneuron markers Calb2 and Som, the inhibitory 
interneuron markers Gad67 and Dyn, the projection neuron marker Nk1r and the 
immediate early transcript FosB (Fig.6E). I expected to see enrichment of those 
transcripts in the ipsilateral sample, which are stably expressed or induced in pain-
activated neurons. Indeed, I observed enrichment of Som, Nk1r and FosB, but not 
Gad67 and Dyn in ipsilateral sample. Nk1r showed the most consistent enrichment (fc 
2.439±0.166) while Som and ForB levels varied more among samples.  
I then repeated the pS6 IP and this time, amplified the collected mRNA into a 
cDNA library for sequencing following the protocol developed by Picelli and 
colleagues (Picelli et al., 2014). Before I proceeded to sequencing, I tested the cDNA 
library again with qPCR. Since I had more samples to test in this experiment, I only 
tested the mRNA expression of Nk1r, c-Fos, FosB and Gad67 (Fig.6F), in order to fit 
all the samples in one 96-well plate. In contrast to the consistent enrichment of Nk1r 
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previously observed, I found great variance in Nk1r expressions in these samples (fc 
1.627±0.566) and possible reasons will be discussed in the later section. Nevertheless, 
enrichment of FosB as well as non-changed expression of Gad67 were detected, 
which are consistent with the previous qPCR shown in Fig.6E. In addition, I could 
show a consistent enrichment of c-Fos in the ipsilateral samples (fc 3.19±0.216), 
reflecting the induction shown by previous in situ hybridization stainings (Fig.5A). I 
subjected the cDNA library to sequencing on an Illumina next-generation sequencing 
platform. 
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Figure 7: Transcriptome of spinal cord cells activated by formalin-induced acute pain  
7A: Fold changes of a selected listed of immediate early genes (IEGs). All IEGs listed, except Fosl1, 
showed significant enrichment while housekeeping gene Actb showed none (N=3, p<0.05, Deseq2).  
7B: Significantly changed genes (N=3, p<0.05, Deseq2) upon formalin-induced acute pain. The fold 
change of the genes were plotted against their expression level (baseMean). A total of 134 enriched and 
136 de-enriched genes were found, with the majority being lowly (0-150 normalized counts) to 
medium level (150-300 normalized counts) expressed. c-Fos was the gene with the highest fold change 
(fc 2.169) and the most highly expressed enriched-gene was Tubb4a (normalized counts 1938), a 
tubulin beta chain protein. A selected list of differentially expressed genes is summarized in Table 1. 
!30
2.3. Transcriptome of spinal cord cells activated by formalin- and 
capsaicin-induced acute pain 
2.3.1 Transcriptome of spinal cells activated by formalin-induced acute pain  
The MiSeq platform was chosen for its cost-effectiveness, relative short running time, 
and the adequate sequence depth (25 million per run) for my experiment purpose to 
identify robust population markers. The sequencing was performed by EMBL 
Genecore. After I received the sequencing reads, I first checked their qualities using 
FastQC and then performed the sequencing data analysis following the workflow 
developed by Love and colleagues using R (Love et al., 2015) and obtained a list of 
significantly changed genes (p<0.05) i.e. genes which are differentially expressed in 
ipsi (stimulated)- and contra (control)-lateral samples.  
• Immediate early gene expression, as internal quality control 
I first checked for the presence of immediate early genes (IEGs) among the enriched 
transcripts. Immediate early genes are among the first genes to be induced once cells 
are activated and as pS6 immunoprecipitation enriches for transcripts from activated 
cells, IEGs should be enriched in the ipsilateral samples, when compared to the 
contralateral samples. A set of immediate early genes was indeed found (Fig.7A): c-
Fos, FosB, Fosl2, as well as Egr1, Junb, Crem and Fam169a were significantly 
enriched (ipsilateral/contralateral) with the exception of Fosl1. In the case of c-Fos 
and FosB, the sequencing results reflect the pre-sequencing qPCR. Although these 
genes reveal no new information about cellular identity upon formalin-induced acute 
pain, they were a good indication that the sequencing worked as it was able to detect 
the known ipsilateral induction of IEGs. 
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• Differentially expressed genes in the spinal cord following formalin-induced 
pain  
I found in total 270 differentially (ipsilateral/contralateral) expressed genes (p<0.05). 
The fold change of the genes were plotted against their expression level (baseMean, 
Fig.7B). Of the 270, there were 134 enriched and 136 de-enriched genes, with the 
majority being lowly (0-150 normalized counts) to medium level (150-300 
normalized counts) expressed genes. c-Fos showed the highest fold change (fc 2.169) 
and Tubb4a, a tubulin beta chain protein, had the highest expression (normalized 
counts 1938).  
In the qPCR of the non-amplified cDNA (Fig.6E), I could show enrichment of 
Nk1r, Som and FosB in the ipsilateral samples. FosB enrichment was found both by 
qPCR of the amplified cDNA library and in the above list of immediate early genes; 
however, neither Nk1r nor Som were on the list of differentially expressed genes. I did 
not test Som in the amplified cDNA library, but in the case of Nk1r, I found a 
discrepancy between the non-amplified and amplified cDNA. In contrast to the 
consistent 2-fold enrichment I detected in the non-amplified cDNA (Fig.6E), the Nk1r 
expression varied greatly amongst biological replicates after the amplification step (as 
shown by the large error bar in Fig.6F, and it is not in the list of differentially 
expressed genes with a significance of p<0.05). I think the following procedural 
differences in the sample preparation step of the pre-sequencing test sample and the 
actual sequencing library could possibly account for the discrepancy: (1) I used 
Superscript III for the non-amplified sample but Superscript II for the amplified 
library preparation. Superscript III produces more cDNA from smaller mRNA 
fragments while Superscript II is more prone to reverse transcribe full length, intact 
mRNA, making it the preferred reverse transcriptase for cDNA library preparation. In 
addition, Superscript III has the working temperature of 55ºC, much higher than the 
42ºC of Superscript II. As mRNA secondary structure changes by temperature 
(Schuster et al., 1994), Superscript III might have a better access to some transcripts 
e.g. Nk1r than Superscript II does. (2) The additional amplification step is a process 
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with an inevitable bias towards the more abundantly expressed genes. Nk1r was 
detected at high cycle numbers in the qPCR using non-amplified cDNA, which 
indicates its low expression level and potentially explains its variance after the 
amplification step.  
Which are the differentially expressed genes? Table 1 shows a list of 10 selected 
genes with high statistical significance and known neuronal functions or CNS 
expression. Apart from c-Fos, Pcdhb16 and Ppp1r3c were the top two enriched genes 
with also highest significance. Pcdhb16 belongs to a cadherin family specifically 
expressed in central nervous system and is believed to be involved in the 
establishment and function of specific cell-cell neural connections (Junghans et al., 
2008). Ppp1r3c, protein phosphatase-1 regulatory subunit 3C, is better known by the 
more indicative name of Protein targeting to glycogen (Ptg). PTG protein guides 
Protein Phosphatase-1 (PP1) to Glycogen Synthase (GYS), resulting in the de-
phosphorylation and activation of the latter. Studies of Ptg have shown that it is a 
main regulator of glycogen synthesis in brain astrocytes (Falkowska et al., 2015). All 
ten genes except Ptg have known neuronal involvement, although not all in the pain 
context. Functions aside, I continued to verify these 10 genes using qPCR to confirm 
if they were indeed enriched or de-enriched in the activated cells of dorsal spinal cord 
by formalin-induced acute pain. But before I went on with the verification 
experiments, I performed another phospho-ribosome profiling. All the above-
described experiments were conducted using the formalin pain model, and in order to 
have a better understanding whether the identified differentially expressed genes are 
specific to formalin-induced pain or they are general to peripheral painful stimuli, I 
performed the same profiling and sequencing experiment using another widely used 
acute pain model, the capsaicin-induced pain model. 
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Figure 8: Transcriptome of spinal cord cells activated by capsaicin-induced acute pain.  
8A: Fold changes of a selected listed of immediate early genes (IEGs). Unlike in 7A, no IEGs were 
found enriched (N=3, p value by Deseq2).  
8B: Significantly changed genes (N=3, p<0.05, Deseq2) upon capsaicin-induced acute pain. The fold 
change of the genes were plotted against their expression level (baseMean). There were in total 818 
differentially expressed genes, with 424 enriched and 394 de-enriched. Snap25, a SNARE protein, had 
the highest normalized counts of 33199. A selected list of differentially expressed genes is summarized 
in Table 2. 
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2.3.2 Transcriptome of spinal cells activated by capsaicin-induced acute pain  
Apart from formalin, capsaicin is another commonly used substance to induce 
chemical pain. I therefore repeated the above-described phospho-ribosome profiling 
experiment to obtain the transcriptome of spinal cells activated by capsaicin-induced 
acute pain. I first used same pS6 IP and cDNA library preparation protocols as before, 
however, I was not able to get a good amount of amplified cDNA. Therefore I 
doubled the amount of pS6 antibody used during the antibody incubation step and 
collected the mRNA, which was then subjected to library preparation, sequencing and 
data analysis following the same protocol as above described.  
• Immediate early gene expression, as internal quality control 
I again first checked for the presence of immediate early genes (IEGs) in the analyzed 
list of differentially expressed genes (p<0.05). However, none of the genes in Fig.7A 
were found to be differentially expressed (Fig.8A). It was puzzling, but I reasoned 
that since capsaicin-induced pain is often considered as a milder, shorter-lasting 
model of acute pain (LaMotte et al., 2011), the expression pattern of IEGs could be 
different from that of formalin-induced pain.  
• Differentially expressed genes in the spinal cord following capsaicin-induced 
pain  
Surprisingly I observed considerably more differentially expressed genes identified in 
the sequencing of transcripts from cells activated by capsaicin-induced pain, 818 in 
total (Fig.8B). 424 of these genes were enriched and 394 de-enriched. The baseMean 
of this experiment also spun a much larger scale, with the highest normalized count of 
33199 assigned to Snap25, a SNARE protein. This indicates that my sequencing depth 
was much higher than in the formalin pain experiment. The double amount of pS6 
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antibody used in the immunoprecipitation could be one element contributed to the 
higher amount of mRNA collected. 
The top 10 enriched and de-enriched genes are listed in Table 2, with their known 
functions and fold changes. The most highly enriched gene was Lppr2, a membrane 
protein belonging to the PA-phosphatase related phosphoesterase family. It is known 
to show dynamic expression regulation during brain development and neuronal 
excitation (Cohen et al., 2015), which would potentially point to a involvement in 
pain processing. The most highly de-enriched gene was Thg1l, a mitochondria 
protein, whose mutation has been reported to result in cerebellar ataxia and 
developmental delay (Edvardson et al., 2016). Among these ten genes, two have been 
shown to be involved in pain processing: Btbd17 has been reported to be up-regulated 
following spinal cord injury (Koehn et al., 2016) and Lrp1 has been studied in the 
context of microglia activation and neuroinflammation (Yang et al., 2016).  
• Comparison of RNAseq results of the formalin and capsaicin pain models 
After I obtained the transcriptome from capsaicin pain-activated spinal cells, I 
compared it with the transcriptome of formalin pain-activated spinal cells. I found a 
surprisingly low number of differentially expressed genes in common: a total of 7 
overlapping genes with p<0.05, and 56 if the significance cut-off is extended to 0.1.  
In addition to analyze the sequencing data with DESeq2, I also performed t-tests 
directly on the count numbers (normalized to total reads per sample) and obtained lists 
of differentially expressed genes in formalin and capsaicin pain models.  Using t-tests, 
I found 24 overlapping genes between the two pain models. Comparing the list of 56 
by DESeq analysis and the list of 24 by t-tests, I identified 5 common genes (listed in 
Table 3 with their known functions and fold changes from both sequencing 
experiments). These 5 genes, together with the 10 genes from Table 1, were chosen as 
candidates for the verification experiments.  
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Figure 9: qPCR verification of the sequencing results 
9A: Formalin-induced acute pain: fold changes of candidates in immunoprecipitation-enriched samples 
(IP) and non-enriched lysates, respectively (N=3 or 4). Immediate early gene Atf3 was enriched in both 
immunoprecipitation-enriched samples and non-enriched lysates. c-Fos, Ptg, Pcdhb16, Ano6 and Meg3 
were enriched in IP samples only. Lck, Gab1 and Rem2 showed minor enrichment. The enrichment was 
however no greater than that of house keeping genes Actb and Pp1a, and was thus considered as 
normal fluctuation.  
9B: Capsaicin-induced acute pain: fold changes of candidates in IP and lysate samples (N=3 or 4). 
None of the tested candidates showed clear enrichment. 
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Atf (Bas-Orth et al., 2017), Ppp1r3c (Falkowska et al., 2015), Pcdhb16 (Junghans et al., 2008), Lck 
(Omri et al., 1996), Ano6 (Cho et al., 2012; Jacobsen et al., 2013), Meg3 (R. Qin et al., 2013), Gab1 
(Korhonen et al., 1999), Rem2 (Ghiretti et al., 2014), Cdh3 (Abraira et al., 2017), Cdh18 (J. Lin et al., 
2014) 
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Table1: Selected list of differentially expressed genes in spinal cord cells following formalin-
induced acute pain
Gene name Known functions Fold change
Atf3 • Transcription factor 

• Known interactor of TRPV1

• Injury marker 
1.386
Ppp1r3c (PTG) • Protein phosphatase-1 regulatory subunit

• Targeting PP1 to glycogen synthase   
1.833
Pcdhb16 • Protocadherin 

• Establishment and function of specific cell-cell 
neural connections
1.747
Lck • Tyrosine kinase

• Known brain expression, function yet unclear
0.739
Ano6 • Cation channel 

• High reservation to Ano1, a chloride channel in 
nociceptive DRG neurons
1.406
Meg3 • linc RNA

• Neuron apoptosis 
1.345
Gab1 • Neurite outgrowth 1.474
Rem2 • Negative regulator of dendritic complexity 1.444
Cdh3 • Layer specific expression in spinal cord 1.235
Cdh18 • CNS specific cadherin 

• Known involvement in synaptic adhesion, axon 
outgrowth and guidance
1.271
Lppr (Cohen et al., 2015), Kcnq2 (Soh et al., 2014), Btbd17 (Koehn et al., 2016), Pcdhgb6 (Kuhn et al., 
2016), Lrp1 (Yang et al., 2016), Thg1l (Edvardson et al., 2016), Shox2 (Dougherty et al., 2013), Spp1 
(Yamamoto et al., 2011), Hells (Han et al., 2017); Klf15 (Takashima et al., 2010; Ohtsuka et al., 2011), 
Mvk (Siemiatkowska et al., 2013), Sez6l (Gorlov et al., 2007), Mmd (Q. Liu et al., 2012). 
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Table2: Top 10 differentially expressed genes in spinal cord cells following capsaicin-induced 
acute pain
Gene name Known functions Fold change
Lppr2 • Known involvement in brain development and 
neuronal excitation 
1.701
Kcnq2 • Potassium channel unit

• Speculated involvement in neuronal excitability 
1.650
Btbd17 • Up-regulated after spinal cord injury 1.607
Pcdhgb6 • CNS specific protocadherin 

• Known involvement in synaptic adhesion, axon 
outgrowth and guidance
1.582
Lrp1 • Suppresses microglial activation after 
neuroinflammation
1.579
Thg1l • Mitochondrial protein whose mutation is linked 
to cerebellar ataxia and developmental delay
0.648
Shox2 • Marks a subpopulation excitatory spinal 
interneurons involved in locomotion 
0.654
Zfp472 • Zink finger protein 0.661
Spp1 • Expressed by spinal motor neuron 0.661
Hells • Regulates self-renewal/proliferation of neural 
stem cells.
0.678
Table 3: Overlapping candidates from formalin (For) and capsaicin (Cap) sequencings
Gene name Known functions Fold change (For/Cap)
Meg3 • linc RNA

• Known involvement in cancer
1.345 1.348
Klf15 • Transcription factor

• Known involvement in neuronal stem cell 
diﬀerentiation and glycogenesis
1.457 1.336
Mvk • Mevalonate kinase, a peroxisome enzyme 1.357 1.368
Sez6l • Seizure 6-like

• Known involvement in lung cancer
1.309 1.368
Mmd • Monocyte To Macrophage Diﬀerentiation 
Associated

• suggested to be an ion channel
1.494 1.247
2.4 Verification of sequencing results 
2.4.1 verification by qPCR 
In order to verify that the sequencing experiments faithfully identified the 
differentially expressed transcripts, I performed qPCR to determine the changes of 
candidates mRNA. I repeated pS6 IP as previously described and collected mRNA 
from both IP eluates and lysates. cDNA was synthesized with Superscript III and 
subjected to qPCR.  
2.4.1.1 qPCR verification of formalin sequencing candidate genes 
I started with the set of 10 transcripts descried in Table 1 as they were detected with 
high significance and therefore constitutes my best candidates. As they were identified 
in the spinal cells activated by formalin-induced pain, I continued with the formalin 
pain model in this qPCR verification experiment. In addition to the genes listed in 
Table 1, I also included immediate early gene c-Fos. Actb and Pp1a were used as 
housekeeping genes.  
It is important to distinguish between the two conditions that would result in 
enrichment in the IP samples: 1) the gene is induced in the pS6-positive cells by the 
given stimulation, or 2) the gene is stably but specifically expressed in the pS6-
positive cells. The lysates were included in this case to distinguish between the two 
possibilities. If the gene is induced, the induction should also be detectable in plain 
lysates, although the fold change could be diluted by the non-activated cells around. If 
the gene is stably expressed in a group of cells, there would be no difference in the 
ipsi- to contra-lateral lysate samples.  
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Of the genes tested, c-Fos, Atf3, Ptg, Pcdhb16, Lck, Ano6 and Meg3 showed 
enrichment in IP samples (Fig.9A). Enrichment of Atf3 was also detected in the lysate. 
Therefore Atf3 expression is induced by formalin-induced acute pain. As c-Fos 
expression is clearly induced by formalin pain as previously shown by in situ 
hybridization (Fig.5A), it was surprising that no c-Fos enrichment was detected in the 
lysate. It is possible that the number of c-Fos positive neurons is relatively small 
compared to the total amount of cells, and the induction is masked in lysate. On the 
other hand, Pcdhb16 and Meg showed enrichment in the lysate, indicating they could 
be induced genes, although the samples bore relatively high variation. Gab1 and 
Rem2 showed similar variations as the housekeeping genes Actb and Pp1a, and thus 
were considered not enriched. Cdh3 and Cdh18 qPCR failed to detect the transcripts. 
This qPCR result suggests that c-Fos, Atf3, Ptg, Pcdhb16, Lck, And6 and Meg3 were 
indeed enriched by pS6 immunoprecipitation. 
2.4.1.2 qPCR verification of the overlapping candidates from formalin and 
capsaicin sequencings 
The qPCR verification using the formalin pain model largely correlates with the 
sequencing result. Therefore, I decided to perform a second round of qPCR using the 
capsaicin pain model, to verify that the 5 overlapping enriched genes of the two 
sequencings are indeed differently expressed and to confirm that there are common 
genes involved in processing both types of acute pain (Table 3). In this round, none of 
the genes were clearly enriched in either IP or lysate samples (Fig.9B).  
Although most of the qPCR results of the formalin pain model fit the sequencing 
data, it failed to detect c-Fos induction in lysate. Considering the experimental 
shortcomings of qPCR, that I can not retrospectively check how much tissue I 
collected or to which lamina layer the dissection reached, I decided to switch to in situ 
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hybridization as the mean of verification, as I could decide what area to quantify, as 
well as visually examine the overlap between a transcript and pS6. 
2.4.2 Verification by in situ hybridization 
I continued to use the candidates from Table 1, and the formalin pain model, as qPCR 
indicates that many of them recapitulate the sequencing result (Fig.9A) and my aim 
here is to verify that the sequencing results represent the actual molecular changes. I 
designed and cloned in situ hybridization probes for Atf3, Ptg, Pcdhb16, Lck, And6 
and Meg3, as qPCR suggested that they are enriched in ipsilateral IP samples, as well 
as Cdh3 and Cdh18, despite that the qPCR did not detect their mRNA. In addition, I 
also included Som, Dyn and MafA as positive controls since they mark subgroups of 
dorsal horn neurons involved in pain processing (Xu et al., 2008; Del Barrio et al., 
2013; Duan et al., 2014a; Christensen et al., 2016; Gutierrez-Mecinas et al., 2016). I 
then performed in situ hybridization on fresh frozen spinal cord cross-sections from 
mice sacrificed 2 hours after intraplantar formalin injection. After the in situ 
hybridization, I did immunofluorescent staining against pS6 on the same sections to 
visualized the cells activated by formalin-induced pain.  
2.4.2.1 Co-staining of candidate and control genes with pS6 
Co-stainings of candidates (in situ hybridization) and pS6 (immunofluorescence) on 
spinal cord cross-sections are shown in Fig.10A-K. Cdh3, Cdh18, Pcdhb16, Meg3 and 
Ano6 are not induced by peripheral painful stimuli. Their expressions were observed 
in both ipsi- and contra-lateral spinal cord. Cdh3 showed a nice dorsal lamina III 
specific expression, while the other two cadherins, Cdh18 and Pcdhb16, had a broader 
expression throughout the dorsal horn. Meg3 was the most ubiquitously expressed 
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transcript. Ano6 shared a similar pattern as Cdh18, i.e. expressed at a medium level 
throughout the dorsal horn. All of these genes showed partial overlap with pS6. 
Atf3, Ptg and c-Fos showed ipsilateral specific expression. There were very few 
Atf3 positive cells, suggesting that the sensitivity of the sequencing was good. All the 
Atf3 cells were also pS6 positive. c-Fos also showed complete overlap with pS6. 
However, there were considerably more pS6-positive cells than c-Fos-positive 
neurons. The different expression dynamics (c-Fos mRNA is detected as early as 5 
minutes after stimulation and starts to degrade after 20 minutes (S. P. Hunt et al., 
1987); while pS6 expression reaches its peak 1 hour after stimulation and only start to 
decline after 2 hours, Fig.5E) could certainly be one explanation, but the additional 
pS6 positive cells raised the question whether there are other cells than neurons 
activated by formalin-induced pain. This thought was followed up and will be shown 
in the next section. The third induced gene was Ptg. Based on previous qPCR, I did 
not expect to find Ptg as an induced gene, as I did not detect its enrichment in the 
lysate. Nevertheless, Ptg in situ hybridization showed a clear ipsilateral specific 
expression through the dorsal horn, with however only limited co-localization with 
pS6 (white arrow). Ptg has not been previously reported to be a pain-induced gene.  
The three dorsal spinal cord specific ‘pain’ genes (Som, Dyn and MafA) I selected 
as positive controls also showed dorsal horn expression as previously reported (Xu et 
al., 2008; Del Barrio et al., 2013; Duan et al., 2014a; Christensen et al., 2016; 
Gutierrez-Mecinas et al., 2016). After imaging the co-stainings, I continued to the 
quantification of them. 
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Figure 10: In situ hybridization verification of the sequencing results  
10A-K: Expression pattern of candidate genes (red, in situ hybridization) and pS6 (green, immunofluorescence) 
in L4 dorsal spinal cord. All candidates stained showed partial or complete co-localization with pS6.  
(A-C): Cadherins. Cdh3 (10A) expression was lamina III specific while Cdh18 and Pcdhb16 (10B and C) 
spread through the dorsal horn.  
(D-E): LncRNA Meg3 (10D) and ion channel encoding Ano6 (10E) both showed ubiquitous expression patterns.  
(F-H): Atf3, Ptg and c-Fos were specifically induced in the ipsilateral dorsal horns.  
(I-K): Known dorsal spinal cord ‘pain’ genes. Som (10I) and MafA (10K) spread through the dorsal horn, with 
most signals in lamina III. Dyn (10J) expression were found in lamina I and II. 
Figure 11: Quantification of in situ hybridization and sequencing results  
11A: Percentage of candidate-gene expressing cells among pS6 positive cells in ipsi- and contra-lateral 
dorsal spinal cord were calculated, respectively. None of the candidates showed a significant ipsi-
contra difference, however the 3 known dorsal horn specific genes (Som, Dyn and MafA) showed 
significant enrichment in ipsilateral sides (N=3, t-test).  
11B: Reads of the same genes from sequencing. All the candidates had significantly higher reads in 
ipsilateral than in contralateral samples. No enrichment could be detected for the known dorsal horn 
‘pain’ genes (N=3, t-test).  
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2.4.2.2 Quantifications of images and comparison to sequencing data 
Atf3 and c-Fos showed clear co-localization with pS6 and are known activity markers, 
while Ptg showed only limited overlap with pS6, they were therefore excluded from 
the quantification of co-localizations.  
I first counted the positive cells for all other candidates and pS6 in dorsal lamina I-
III separately to avoid bias. I then overlaid the images to determine the double 
positive cells. Percentage was calculated as the portion of double-positive (candidate 
and pS6) cells in the pS6-positive population, for ipsilateral and contralateral sides, 
respectively. The quantification is shown in Fig11A, and normalized sequencing reads 
of these genes are plotted in Fig.11B.  
The two graphs show contradicting results, when comparing to data shown in 
previous qPCR verifications. Firstly, by co-staining, the percentage of cells expressing 
both the candidate transcript and pS6 in the total pS6 population was not significantly 
different in the ipsi- and contra-lateral sides, contradicting the sequencing results, 
which showed significant enrichment of the candidate mRNA in the ipsilateral side. 
Secondly, Som, Pdyn and MafA were all significantly enriched in the pS6-positive 
cells in the ipsilateral sides over contralateral controls by in situ hybridization; 
whereas none of the three were identified by the phospho-ribosome profiling. To sum 
up, I was unable to verify candidate transcripts from the phospho-ribosome profiling 
experiment of formalin-induced pain by in situ hybridization. Furthermore, the 
method failed to identify known markers of neurons in the pain pathways. I did not 
achieve the goal of using pS6 immunoprecipitation to identify stable marks for spinal 
cells activated by peripheral painful stimuli. Possible reasons will be discussed later in 
the discussion part.  
Nevertheless, I identified a novel transcript Ptg: despite its limited overlap with 
pS6, it was robustly induced upon painful stimuli. I therefore went on to characterize 
the involvement of Ptg in the spinal pain response. 
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2.5 Protein targeting to glycogen (Ptg) as a pain-induced transcript  
I could show that Ptg mRNA is strongly induced on the ipsilateral side of the dorsal 
spinal cord by formalin-induced acute pain (Fig.12A). Ptg stands for protein targeting 
to glycogen, one of the few genes with a self-explanatory name. PTG protein is a 
subunit of protein phosphatase 1 (PP1) which guides PP1 to Glycogen Synthase 
(GYS). PP1 de-phosphorylates GYS, resulting in the activation of the latter, and 
glycogen is synthesized (Brady et al., 1997; Printen et al., 1997). In the brain, PTG is 
found predominantly in astrocytes and plays an important role in astrocytic glycogen 
synthesis (Allaman et al., 2000). On the other hand, abnormal excessive brain 
neuronal glycogen lead to the neurodegenerative Lafora disease. In Lafora disease 
studies, it has been reported that knocking down or out Ptg partially relieved the 
otherwise lethal symptoms (Guerrero et al., 2011; Turnbull et al., 2011; Turnbull et al., 
2014).  
2.5.1 Ptg localization and co-staining of Ptg with neuronal and glial markers 
In order to identify the type of spinal cells in which Ptg is induced, I performed co-
staining of Ptg (in situ hybridization) with the following cell type specific markers 
(immunofluorescence): GFAP (astrocytes), NeuN (neurons) and IBA1 (microglia). I 
continued using the formalin pain model. Fig.12B shows that filamentous GFAP 
signal enclosing perinuclear Ptg, while there was no overlap of Ptg with the neuronal 
marker NeuN or microglia marker IBA1. Therefore, consistent with previous study 
about brain Ptg expression (Cataldo & Broadwell, 1986), Ptg is induced in spinal 
astrocytes following formalin-induced acute pain.  
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• pS6 marks reactive astrocytes 
In the co-staining of Ptg and pS6, I observed limited overlapping of the two signals 
(Fig.12A), and now with the knowledge that Ptg is predominantly in astrocytes, I 
asked whether pS6 also marks the astrocytes that are activated by formalin-induced 
pain i.e. reactive astrocyte? To test this, I performed co-staining of pS6 with the 
astrocyte marker GFAP (immunofluorescence). Fig.12C show GFAP positive 
filaments enclosing pS6 signals. Therefore, pS6 also marks reactive astrocytes. This 
might explain the above-mentioned observation that there were many more pS6-
positive cells than c-Fos-positive neurons, i.e. a small fraction of pS6 cells are 
reactive astrocytes which does not express c-Fos upon activation.  
But there is one more possible cause to the discrepancy of more pS6- then c-Fos-
positive cells: the different dynamics of c-Fos and pS6. Although induced by the same 
signaling pathways, c-Fos mRNA is reported to be induced already 5 minutes after 
stimulation and would reach its peak level after 20 minutes (S. P. Hunt et al., 1987); 
whereas the phosphorylation of ribosome reaches its peak between between 1 hour to 
2 hours after stimulation (Fig.5E). As the spinal cord tissue here was collected 2 hours 
after formalin injection, it is possible that some c-Fos mRNA has by then degraded.  
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Figure 12: Ptg mRNA expression is induced in spinal astrocytes by formalin-induced acute pain  
12A: Ptg mRNA (red, in situ hybridization) was induced at dorsal spinal cord, ipsilateral to formalin 
injection. The induction spread through the dorsal horn and showed limited overlap with pS6 (green, 
immunofluorescence).  
12B: Co-stainings of Ptg (red, in situ hybridization) and cell type markers (green, immunofluorescent). 
Ptg were surrounded by filamentous astrocyte marker GFAP (left) but showed no co-localization with 
neuronal marker NeuN (middle) or microglia maker IBA1 (right).  
12C: Immunofluorescent co-stainings of pS6 (red) and astrocyte marker GFAP (green). Partial co-
expression of pS6 and GFAP were observed (white arrow).  
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2.5.2 Ptg RNA inductions in other forms of pain 
Ptg is induced in spinal astrocytes by formalin-induced acute pain. To test whether the 
induction of Ptg is specific to formalin pain or is a general response to peripheral 
painful stimuli, I performed a series of in situ hybridization to examine the expression 
of Ptg mRNA in other acute and chronic pain models.  
Apart from the previous described formalin-induced acute pain model, I also found 
induction of Ptg mRNA also by capsaicin-induced acute pain (Fig. 13A). However, 
when examining the samples collected at later time points after formalin pain (24 and 
48 hours, Fig.13C and D), I did not find any more Ptg mRNA expression. Similar to 
the formalin model, I observed strong Ptg induction 2 hours post stimulation (Fig.
13B) but not after 3 days (Fig.13E). I also tested Ptg expression in the spared nerve 
injury (SNI) model. SNI is a model for neuropathic pain. SNI neuropathic pain is 
induced by severing two of the three branches of the sciatic nerve (the tibial nerve and 
the common peroneal nerve), leaving the sural nerve intact. To avoid the influence 
from surgical pain, I did not measure at the 2-hour time point, but examined the Ptg 
mRNA expression 7 days after the surgery. There was no Ptg mRNA detected. These 
data suggest that Ptg is induced within 2 hours after acute pain stimulation (formalin 
or capsaicin) and is transiently expressed. It is also induced in CFA inflammatory pain 
model, but while the pain persists for at least 7 days (Fehrenbacher et al., 2012), Ptg 
induction is observed only in the acute phase i.e. two hours after injection. Whether 
Ptg is also induced in the acute or subacute phase of SNI neuropathic pain model is, at 
this stage, not clear. Ptg inductions in different pain models are summarized in Fig.
13G. 
With the above experiments, I showed that despite the unsuccessfully identification 
of stable markers using phospho-ribosome profiling, I identified Ptg as a pain-induced 
gene in spinal astrocytes and its transient induction was found in various pain models. 
In the following sections, I continued to explore the functional output of Ptg.  
!51
!52
Figure 13: Ptg mRNA is transiently induced in acute and chronic pain models 
13A: Capsaicin-induced acute pain. Ptg mRNA (red, in situ hybridization) was observed in ipsilateral dorsal 
spinal cord 2 hours after stimulation.  
13B and E: CFA-induced inflammatory pain. Ptg mRNA expression was observed 2 hours (red, in situ 
hybridization) after intraplantar CFA injection in ipsilateral dorsal spinal cord, but not 3 days after (purple, in 
situ hybridization).  
13C and D: Formalin-induced acute pain. No more Ptg mRNA expression (red, in situ hybridization) was 
detected 24 hours or 48 hours after formalin injection.  
13F: SNI neuropathic pain. No Ptg mRNA expression was observed 7 days after the surgery (NBT/BCIP, in 
situ hybridization). No earlier time points were examined.  
13G: Schematic summary of Ptg mRNA induction in different pain models. It is transiently induced at 2 
hours after onset of formalin/capsaicin/CFA-induced pain.
2.6 Spinal glycogen profile of acute and chronic pain models 
If Ptg mRNA is induced by peripheral painful stimuli, would there be a functional 
consequence? As Ptg is known as the main regulator of astrocytic glycogenesis 
(Ruchti et al., 2016), I studied the glycogen profiles of different pain models in order 
to check whether glycogen level is altered following Ptg mRNA induction. 
2.6.1 Formalin-induced acute pain 
I first examined the temporal profile of glycogen in the formalin-induced acute pain.  I 
used an commercial kit to measure the glycogen level in the spinal cord tissue (see 
Material and Methods). The measurement includes two enzymatic reactions: (1) the 
hydrolysis of glycogen to glucose by glucoamylase and (2) the specific oxidization of 
glucose which produces a product that in turn reacts with OxiRed probes to generate 
fluorescence. The fluorescence is then measured by spectrophotometer and the 
glycogen level could be calculated. For this I collected dorsal spinal cord samples 
(ipsi- and contra-lateral) at different time points after intraplantar formalin injection, 
as well as from naive mice as the baseline i.e. the basal glycogen level in spinal cord. 
Glycogen levels were normalized to protein content and are plotted in Fig.14A. Naive 
mice exhibited scattered glycogen levels (detected levels ranged from 0.141 to 0.409 
(µg/µL)/mg protein). Individual differences were as large as four-fold. Pairing the 
ipsi- and contra-lateral measurements (though no injection was admitted, the two 
sides are assigned ipsi- and contra-lateral for consistency and convenience) revealed 
comparable glycogen levels of the two sides, i.e. the mouse with high glycogen level 
at the ipsilateral side would also have high level at the contralateral side.  
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The first time point measured was two hours after injection, as it was the time 
when Ptg mRNA expression was observed. Although showing no difference between 
the two sides (0.188±0.022 vs 0.184±0.019 (µg/µL)/mg protein), glycogen levels at 2 
hours after formalin injection seemed to have smaller individual variances, when 
compared to the scattered ‘naive’ data points.  
Six hours after unilateral formalin injection into the hind paw, there was a 
significant difference in the glycogen levels between ipsi- and contra-lateral tissue 
samples: the ipsilateral glycogen levels doubled (0.400±0.015 vs 0.188±0.008 (µg/
µL)/mg protein). The ipsilateral glycogen levels remained significantly higher than 
that of the contralateral control side at the third time point (24 hours post injection) 
examined (0.323±0.025 vs 0.160±0.009 (µg/µL)/mg protein).  
The elevated glycogen levels dropped 3 days after injection, back to similar 
amount as in contralateral tissue (0.097±0.0193 vs 0.092±0.0204 (µg/µL)/mg 
protein).  
Due to the scattered baseline, the ipsi-/contra-lateral ratio of glycogen levels was 
chosen to better represent the data. As previously explained, the scatter glycogen 
measurements of naive mice were ipsi-/contra-lateral wise paired. The ratio of 
glycogen levels of the ipsi- and contra-lateral tissue was calculated and shown in Fig.
14B. For naive mice, the ratios of glycogen levels in these mice were close to 1 
(0.939±0.044), and similar ratios were observed two hours after formalin injection 
(1.026±0.093). In contrast, formalin injection caused a 2-fold increase in glycogen 
levels after six (2.044±0.118) and 24 hours (2.008±0.083). After 3 days, the ratio 
dropped back to 1 (1.078±0.062). These two plots (Fig.14A-B) showed a transient 
increase in glycogen level upon formalin-induced acute pain, that was delayed by 
approximately four hours in comparison to the Ptg mRNA expression. These data 
suggest that an acute painful stimulus triggers Ptg mRNA expression in dorsal spinal 
cord, which in turn leads to glycogen synthesis.  
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*legends on the next page 
 
!55
Figure 14: Spinal glycogen profiles of different pain models  
Glycogen levels of ipsi- and contra-lateral dorsal spinal cord (L2 to 6) were measured. 
14A and B: Formalin-induced acute pain. (A): Naive mice showed a spread in their glycogen levels but 
the ipsi- and contra-lateral levels of each mouse were paired (between 0.141 and 0.409 (µg/µL)/mg 
protein). 2 hours after formalin injection, similar glycogen levels in ipsi- and contra-lateral tissue were 
found (0.188±0.022 vs 0.184±0.019 (µg/µL)/mg protein), while 6 hours after injection, ipsilateral 
glycogen levels doubled (0.400±0.015 vs 0.188±0.008 (µg/µL)/mg protein). The ipsilateral glycogen 
levels remained significantly higher than that of the contralateral side 24 hours after injection 
(0.323±0.025 vs 0.160±0.009 (µg/µL)/mg protein). The elevated ipsilateral glycogen level dropped 
back to similar amounts as in contralateral tissue 3 days after (0.097±0.0193 vs 0.092±0.0204 (µg/µL)/
mg protein).  
(B): Ratios of ipsi/contra-lateral glycogen levels. Corresponding to the paired ipsi-contra data in 15A, 
the ipsi/contra ratios of the scattered glycogen levels were around 1 in naive mice (0.939±0.044). 
Similar ratios were obtained 2 hours after injection (1.026±0.093). 6 hours after formalin injection, the 
ipsi/contra ratios increased (2.044±0.118) and remained high until 24 hours  after injection 
(2.008±0.083). It dropped back to 1 after 3 days (1.078±0.062) (N=3 or 5, t-test).     
14C: Capsaicin-induced acute pain. Ratios of ipsi/contra glycogen levels increased 6 hours after 
injection (1.419±0.046) and dropped 24 hours after (1.034±0.063) (N=2 or 3, t-test).  
14D: CFA-induced inflammatory pain. Ratios of ipsi/contra glycogen levels rose 6 hours after injection 
(2.165±0.042) and were still elevated 3 days after injection (1.362±0.127). It dropped back after 7 days 
(1.024±0.046)  (N=4, t-test).  
14E-G: SNI neuropathic pain.  
(E): Left: sham operated mice set the baseline glycogen levels at (0.105±0.002 and 0.115±0.006 (µg/
µL)/mg protein). Ipsilateral glycogen levels were found elevated 2 weeks after SNI surgery 
(0.167±0.007 (µg/µL)/mg protein), while those of contralateral sides stayed similar to baseline levels 
(0.087±0.005 (µg/µL)/protein). Both ipsi- and contra-lateral glycogen levels increased 8 weeks after 
the surgery (0.175±0.009 and 0.162±0.004 (µg/µL)/mg protein). Pregabalin (PG) treatment did not 
change the glycogen levels (0.197±0.007 and 0.190±0.009 (µg/µL)/mg protein). Right: Additional 
capsaicin injection (Cap) in SNI operated mice resulted in even higher ipsilateral glycogen levels as in 
sham mice (sham: 0.181±0.021, SNI 2 weeks+Cap: 0.313±0.035, SNI 8 weeks+Cap: 0.330±0.048 (µg/
µL)/mg protein). The additional capsaicin injection did not change contralateral glycogen levels (sham: 
0.105±0.002, SNI 2 weeks+Cap: 0.105±0.016, SNI 8 weeks+Cap: 0.168±0.014 (µg/µL)/mg protein) 
(N=3, t-test). 
(F): Ratio of ipsi/contra glycogen levels for sham, SNI 2 weeks and SNI 2 weeks+Cap mice from 15E. 
As there were no changes in glycogen levels for sham mice, the ratio stayed at 1 (0.915±0.026). 
Ipsilateral glycogen levels are 1.956±0.186 times higher than contralateral in SNI 2 weeks mice, while 
the additional additional capsaicin stimuli brought the ratio further to 3.027±0.142.  
(G): Additional noxious mechanical stimuli on sham and SNI operated mice. Glycogen levels in SNI 2 
weeks+Mec mice (0.178±0.010 vs 0.167±0.007 (µg/µL)/mg protein) were not different from those of 
SNI mice from 15E, while on the contrary, mechanic stimulation on sham operated mice resulted in 
elevated glycogen levels in both ipsi- and contra-lateral sides (0.321±0.0494 vs 0.226±0.025 (µg/µL)/
mg protein) (N=3, t-test) . 
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2.6.2 Capsaicin-induced acute pain 
To study whether the observed glycogen increase is shared by other pain models, I 
then performed the similar experiment to obtain the spinal glycogen profile of 
capsaicin-induced acute pain (Fig.14C). Similar to the formalin pain model, I 
observed an increase in ipsilateral glycogen levels 6 hours after stimulation (ratio: 
1.419±0.046), but glycogen levels already returned to the baseline 24 hours after 
capsaicin application (ratio: 1.034±0.063), resulting in a smaller and shorter peak than 
formalin acute pain. The different dynamics possibly reflects the intensity and 
duration of the two acute pain models. 
2.6.3 CFA-induced inflammatory pain 
In order to assess whether inflammatory pain model also show a similar dynamics in 
glycogen levels, I next tested the Complete Freund’s Adjuvant (CFA) inflammatory 
pain model (Fig.14D). CFA inflammatory pain reaches its peak 24 hours after the 
injection and persists for at least 7 days (Fehrenbacher et al., 2012). Similar to the two 
acute pain models, increased levels of glycogen were detected in the ipsilateral 
samples 6 hours after CFA intraplantar injection (ratio: 2.165±0.042). I also measured 
glycogen levels 3 days and 7 days after the CFA injection since CFA inflammation 
persists for a longer time. While ipsilateral glycogen levels dropped back to baseline 3 
days after formalin injection, it was still elevated 3 days after CFA injection (ratio: 
1.362±0.127) but returned to baseline levels within 7 days (ratio: 1.024±0.046).  
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2.6.4 SNI neuropathic pain 
I next asked what about the glycogen levels in chronic pain models? Glycogen levels 
were measured two and eight weeks after the neuropathic pain-inducing SNI surgery. 
Additionally I treated the mice with pregabalin, a GABA analog which is an effective 
medication against neuropathic pain, to determine whether suppressing chronic 
neuropathic pain would affect glycogen levels. I also applied an acute pain stimulus 
(capsaicin) in the SNI model to study the changes of glycogen level when mice are 
subject to two different painful stimuli (Fig.14E-G).  
Although no mRNA induction were observed 7 days after surgery as previously 
shown, a dynamic profile of glycogen levels was uncovered. Ipsilateral glycogen 
levels were found elevated 2 weeks after SNI surgery (0.167±0.007 (µg/µL)/mg 
protein), while contralateral side stayed low (0.087±0.005 (µg/µL)/mg protein), as 
compared to the glycogen levels 2 weeks after sham operation (0.105±0.002 vs 
0.115±0.006 (µg/µL)/mg protein). Interestingly, there was no more ipsi- to contra-
lateral glycogen difference when analyzing the animals 8 weeks after the surgery 
(0.175±0.009 vs 0.162±0.004 (µg/µL)/mg protein). However, instead of the returning 
of the elevated ipsilateral glycogen levels to baseline as observed in the formalin/
capsaicin/CFA pain models, contralateral glycogen levels were increased.  
Treating the animal 8 weeks after surgery with pregabalin (PG) did not change 
their glycogen levels (without PG: 0.175±0.009 and 0.162±0.004 vs with PG: 
0.197±0.007 and 0.190±0.009 (µg/µL)/mg protein). As pregabalin alleviates pain, this 
result indicates that the relief of pain after its induction does not affect glycogen 
levels.  
Both ipsilateral and contralateral glycogen levels change as SNI neuropathic pain 
progresses. Capsaicin was administrated into the ipsilateral hind paw and tissues were 
harvested 6 hours after injection. While contralateral glycogen levels were 
comparable to the corresponding levels in SNI animals without capsaicin injection  (2 
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weeks SNI+Cap: 0.105±0.016 (µg/µL)/mg protein and 2 weeks SNI: 0.087±0.005 
(µg/µL)/mg protein), 8 weeks SNI+Cap: 0.168±0.014 (µg/µL)/mg protein and 8 
weeks SNI: 0.162±0.004 (µg/µL)/mg protein), the ipsilateral glycogen levels were 
significantly higher. Ipsilateral glycogen was already elevated 2 weeks after the 
induction of neuropathic pain, while an additional capsaicin stimulus boosted the 
glycogen level even higher (0.313±0.035 (µg/µL)/mg protein). The same was found 
for mice 8 weeks into neuropathic pain states. With some variances in the readings, an 
additional capsaicin stimulus also increased the glycogen levels further (0.330±0.048 
(µg/µL)/mg protein). To confirm that an acute stimulation on a chronic background 
brings up glycogen levels further than either stimulation alone, I also applied 
capsaicin to sham operated animals. All four conditions (SNI, Sham, SNI+Cap and 
Sham+Cap) shared similar contralateral readings (Fig.14E). Highest ipsilateral 
glycogen levels were found in SNI+Cap mice (0.313±0.035 (µg/µL)/mg protein), 
mildly elevated in SNI or Sham+Cap mice (0.167±0.007 and 0.181±0.021 (µg/µL)/
mg protein, respectively) and remained unchanged in Sham mice (0.105±0.002 (µg/
µL)/mg protein) as well as in all contralateral sides.  
I calculated the ipsi-/contra-lateral ratios for the ‘2 weeks after SNI’ data set. Sham 
mice did not have changes in their glycogen levels, thus resulting in a ratio similar as 
the previous ‘naive’ mice (0.915±0.026). Ipsilateral glycogen levels are 1.956±0.186 
times higher than that of contralateral side in SNI mice, while applying an additional 
pailful chemical stimulus increased the ratio further to 3.027±0.142 (Fig.14F).  
In addition to capsaicin, I tested another acute pain stimulation. SNI operated mice 
are known to develop mechanical hypersensitivity (Richner et al., 2011), and therefore 
painful mechanic stimulation was applied to the ipsilateral paw subjected to SNI 
surgery (Fig.14G). Glycogen levels in SNI+Mec mice were not different from plain 
SNI mice  (0.178±0.010 vs 0.167±0.007 (µg/µL)/mg protein), while on the contrary, 
mechanic stimulation on Sham operated mice showed elevated glycogen levels in 
both ipsi- and contra-lateral sides (0.321±0.0494 and 0.226±0.025 (µg/µL)/mg 
protein). It would seem that painful mechanical stimulus alone can elicit glycogen 
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elevation, but no further increase can be observed when combining painful 
mechanical stimuli with existing mechanical allodynia.  
In summary, in both acute (formalin and capsaicin) and inflammatory (CFA) pain 
models, ipsilateral glycogen levels increased about 6 hours after the induction of pain 
and would return to the baseline after 24 hours to 1 week, depending on the 
persistency of the pain. In neuropathic pain model, an increase in the ipsilateral spinal 
cord glycogen level was also observed, however, as the pain prolonged, the ipsilateral 
glycogen level did not decrease, instead, the contralateral glycogen level increased. 
Moreover, acute chemical pain (capsaicin) applied on mechanical allodynia 
background (SNI) would further increase the glycogen level, but additional acute 
mechanical pain did not.  
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Figure 15: in vitro and in vivo PTG over-expression 
15A: PTG over-expression test in HEK293 cells. Up: Ptg- and control (ctr)-transfected HEK cells were 
collected and loaded on a western blot and blotted with PTG (left) and FLAG (right) antibodies. In Ptg-
transfected cells, both antibodies detected a band of ~40kDa which was absent from the control cells. 
Down: Glycogen level was greatly increased in PTG-expressing HEK cells  as compared to control-
transfected cells (PTG: 2.966 vs ctr: 0.035 (µg/µL)/mg protein). 
15B: AAV viral constructs. 3xFlag-Ptg and Venus were under astrocytic Gfap promotor. 
15C: PTG and Venus over-expression in astrocyte culture. Co-stainings of astrocyte marker GFAP (red) 
and PTG/Venus (green) showed astrocyte-specific expression of the two proteins respectively. 
15D: PTG and Venus over-expression in dorsal spinal cord. Immunofluorescent stainings of dorsal 
spinal cord showed both PTG and Venus (red) expression following virus injection.  
15E: Glycogen measurement after viral over-expression. The PTG over-expressing mice showed a 
significant increase in spinal glycogen level over Venus control mice (1.057±0.187 vs 0.254±0.036 (µg/
µL)/mg protein, N=4, t-test). 
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2.7 The effect of glycogen levels on the pain state 
I found that glycogen levels are elevated in the ipsilateral spinal cord 6 hours after 
acute pain stimulations or CFA induced inflammatory pain. It also increased 2 weeks 
after SNI surgery, and can be elevated further by the application of acute painful 
chemical stimulus on mechanical allodynia background. Does this additional 
glycogen have any effect on the extent of pain? Does it aggravate or alleviate pain? To 
answer these questions I next manipulated the in vivo expression of PTG in mouse 
and also blocked glycogen mobilization. 
2.7.1 PTG over-expression 
In order to increase glycogen levels, I over-expressed PTG using an adenoviral 
approach. To do this I first cloned 3xFlag-Ptg into pcDNA and tested its expression in 
HEK293 cells, meanwhile I cloned the 3xFlag-Ptg into an viral vector under a Gfap 
astrocyte-specific promotor and viral particles were produced by Karin Meyer to 
infect astrocytes in vitro and in vivo. 
2.7.1.1 PTG over-expression in HEK cells 
HEK cells were transfected with pcDNA-3xFlag-Ptg or an empty control vector and 
were collected 48 hours after transfection. Glycogen levels of the lysates were 
measured, and the remaining lysates were subjected to western blotting to detect 
FLAG and PTG.  
Both FLAG and PTG antibodies detected a clear band at the same size (~40kDa), 
which was absent from the transfected negative controls (Fig.15A, up). This result 
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shows that, PTG was correctly expressed in HEK cells and that, since the FLAG 
antibody recognized a protein band of same size as PTG antibody did, FLAG could be 
used to report the presence of PTG.  
PTG expressing HEK cells showed a strong increase in the glycogen levels 
compared to control transfected cells (2.966 vs 0.035 (µg/µL)/mg protein, Fig.15A, 
down), indicating that PTG is not only expressed, but also functional.  
2.7.1.2 Testing pAAV-GFAP-3xFLAG-PTG and pAAV-GFAP-Venus viruses in 
cultured astrocytes 
I next cloned AAV viral constructs encoding astrocytic Gfap promotor and 3xFlag-Ptg 
or mVenus inserts (Fig.15B). Before injecting the virus into mice, I test-infected 
cultured astrocytes with the above AAV virus. Mouse hippocampus primary cultures 
were infected with either the Ptg or Venus encoding AAV virus and kept in culture for 
14 days by Dr. Anna Hertle. The cultured cells were then immuno-stained with 
antibodies against FLAG, Venus and GFAP. Both FLAG or Venus antibodies showed 
co-expression with the astrocyte marker GFAP (Fig.15C), suggesting that the GFAP 
promotor correctly directed the viral expression of the introduced transgender to 
astrocytes.  
2.7.1.3 Over-expression of FLAG-PTG in mouse spinal cord  
After successful test in cultures, viruses were injected in dorsal spinal cord by Dr. 
Manuela Simonetti. I sacrificed the mice 2 weeks after the injection and dissected the 
spinal cord out. I then checked for the expressions of FLAG-PTG and Venus control 
in spinal cord cross-sections by immunofluorescent stainings (Fig.15D). The glycogen 
levels of the infected dorsal spinal cord tissue were also measured. The PTG over-
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expressing mice showed a significant increase in their spinal glycogen level as 
compared to Venus controls (1.057±0.187 vs 0.254±0.036 (µg/µL)/mg protein, Fig.
15E). This indicated the virus successfully infected astrocytes and over-expressed 
FLAG-PTG or Venus. The PTG over-expression resulted in elevated glycogen levels. 
 
Figure 16: Altered pain thresholds in mice with spinal PTG over-expression 
Mice were measured 3 weeks after virus injection, t-test, N=4. 
16A: von Frey mechanical pain threshold. After PTG over-expression, the mice (black) exhibited 
significantly enhanced mechanical sensitivities: 0.07g filament (before:12±4.90%, after: 88±4.90%), 
0.16g filament (before: 68±16.25%, after: 96±4.00%) and 0.4g filament (before: 64±16.00%, after: 
100%). Venus over-expressing mice (green) showed no change before and after virus injection. 
16B: Hargreaves thermal pain threshold. PTG over-expressing mice (black) showed a significantly 
higher thermal sensitivity (response time, before: 9.76±0.62s, after: 6.13±0.76s). Venus over-expressing 
mice (green) showed a non-significant drop in response time (before: 9.027±0.542, after: 
7.554±1.369s). 
16C: Formalin test. PTG over-expressing mice (black) showed a delayed second phase by 10 minutes, 
while the magnitudes of the second phase peaks did not change (PTG: 144.146±30.708s vs Venus: 
159.563±25.710s). 
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2.7.1.4 Pain thresholds in mice over-expressing PTG 
To test if high glycogen levels have an impact on mechanical and thermal pain 
thresholds, I performed the von Frey and Hargreaves test on the PTG over-expressing 
mice. The baseline was measured 3 days before virus injection and both mechanical 
and thermal thresholds were again measured 3 weeks after the injection (Fig.16A and 
B).  
I did not observe a change in von Frey thresholds for the Venus injected control 
mice before and after the over-expression (before: 16.00±11.66%, after: 20±6.32%). 
In contrast to this I found that PTG over-expression significantly sensitized the 
animals to mechanical stimulation. Hence, spinal Ptg over-expression led to 
hypersensitivity upon painful mechanical stimulation (Fig.16A).  
I also found a significantly increased thermal sensitivity in the PTG spinal over-
expressing mice using the Hargreaves assay (Fig.16B). The response time 
significantly dropped from 9.76±0.62s to 6.13±0.76s, while Venus controls changed 
from 9.027±0.542 to 7.554±1.369s, indicating that the viral over-expression itself 
seems to have a slight, but non-significant, effect on thermal thresholds. 
Next I measured the response to chemical pain by the formalin test in the mice 
over-expressing PTG or Venus. Formalin-induced pain elicits behaviors such as 
licking, flinching and paw lifting, and is known to have two phases (Carter & Shieh, 
2010). The first phase starts immediately after the injection and lasts for 10 minutes. 
The second phase kicks in about 15 minutes after the injection and stays for about 50 
minutes. Therefore, the behavior of the mice was video-recorded for 50 minutes after 
formalin injection, and their pain behaviors quantified in bins of 5 minutes (Fig.16C).  
During the first phase (the first 10 minutes), PTG over-expressing mice seem to 
show a slight, but non-significant decrease in their response compared to control 
mice. During the second phase of the formalin response, PTG over-expressing mice 
were found to have a similar but delayed maximal response. Pain behaviors of the 
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control mice reached a maximum (159.6±25.7s) at 35 minutes after formalin 
injection, while the Ptg over-expressing mice exhibited a maximal response of similar 
magnitude (144.1±30.7s) at 45 minutes after injection. Both groups showed a decline 
of pain behaviors after reaching the peak.  
2.7.2 Blocking glycogen mobilization 
In the above section, I showed that elevated spinal glycogen levels following 
astrocytic PTG over-expression lead to altered pain sensitivity and nocifensive 
behaviors, I then wondered what would be the impact if the glycogen cannot be 
utilized? To test this, I used a potent glycogen mobilization inhibitor, 1,4-dideoxy-1,4-
imino-D-arabinitol (DAB). DAB inhibits the activity of glycogen phosphorylase, the 
enzyme that breaks down glycogen into UDP-glucose as the first step of glycogen 
mobilization. DAB was administered by Dr. Manuela Simonetti via intrathecal 
injection 15 minutes prior to intraplantar formalin injection. Again, I recorded the 
behavior of the mice for 50 minutes after formalin injection, and scored their pain 
behaviors (Fig.17). 
The DAB-injected mice showed a significantly suppressed pain behavior during 
the first phase (in the first 5 minutes: 2.6±0.8s vs 21.0±7.1s). There was no significant 
difference in the second phase of the formalin response between DAB-injected and 
control mice (peak at 35 minutes: 57.5±15.9s vs 67.1±23.2s). In this experiment, the 
mice in general exhibited weaker nocifensive reactions compared to those in the 
previous PTG over-expression experiment (second peak: ±67s vs ±150s). As these 
mice were subject to two consecutive isoflurane anesthesia within 15 minutes, the 
stress from short-spaced consecutive rounds of anesthesia (Hohlbaum et al., 2017) 
may have contributed to the reduced overall nocifensive behavior exhibited. 
Nevertheless, DAB seems to suppress pain behavior in the first phase of formalin test, 
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suggesting that the neuronal activity behind this pain behavior reply on astrocytic 
glycogen mobilization. 
 
Figure 17: Intrathecal administration of glycogenolysis inhibitor DAB suppresses formalin test 
response 
Mice received intrathecal injection of either glycogenolysis inhibitor DAB or PBS control, 15 minutes 
before intraplantar formalin injection. The first phase peak was significantly suppressed in DAB 
injected mice (DAB: 2.646±0.843s vs PBS: 20.967±7.084s). Similar second phase pain behaviors were 
observed in DAB or PBS injected mice (N=4, t-test). 
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3. Discussion  
3.1 Molecular profiling of spinal dorsal horn cells activated by 
formalin-induced acute pain 
3.1.2 pS6 marks spinal cells activated by peripheral painful stimuli: not only 
neurons but also astrocyte 
The ribosomal subunit 6 (S6) is phosphorylated upon activation of the PI3-K/mTOR, 
MAPK, and PKA signaling pathways, leading to increased translational activities of 
the ribosome (Knight et al., 2012). The same signaling pathways are also known to 
lead to the expression of activity-dependent genes such as c-Fos (Flavell & 
Greenberg, 2008; Valjent et al., 2011). Several studies have reported overlapping 
pattern of c-Fos and pS6 expression in brain regions activated by fear or aggression 
(Dielenberg et al., 2001; D. Lin et al., 2011). In my thesis work, I used pS6 to mark 
spinal dorsal horn cells activated by peripheral painful stimuli, e.g. formalin-induced 
acute pain. After the induction of unilateral pain, immunofluorescent stainings showed 
specific pS6 expression in the ipsilateral superficial dorsal horn, the spinal cord region 
responsible for pain processing (Section 2.1). I could show that the pS6 staining 
overlaps not only with the neuronal activity marker c-Fos but also with the astrocyte 
marker GFAP, suggesting that pS6 marks also reactive astrocytes.  
Expression of pS6 as a marker for mTOR activity has been previously reported in 
spinal astrocytes (Codeluppi et al., 2009; Sha et al., 2012; Kjell et al., 2014). 
Therefore, I propose the possible application of the phospho-ribosome profiling 
technique to astrocytes. One point to note is that, as illustrated in Fig.18, there are five 
phosphorylation sites on ribosomal protein S6 (p235,236,240,244 and 247). The 
phosphorylation of S6 is believed to occur in an activity-dependent sequential order 
i.e. N-terminal sites (p235/236) are phosphorylated with low, basal activities, while 
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the most C-terminal sites (p244/247) are phosphorylated only upon strong activities 
(Meyuhas, 2008). I used an anti-p240/244 antibody in my study while in the above-
mentioned spinal astrocytes studies (Codeluppi et al., 2009; Kjell et al., 2014), an 
anti-p235/236 antibody was used. Knight and colleagues reported that in 
immunofluorescent stainings, phosphorylation at sites p235/236 and p240/244 are 
both stimuli-specific; however, immunoprecipitation with an anti-p240/244 antibody 
was proposed by Knight and colleagues to yield a more robust enrichment as it would 
only enrich the strongly activated neurons (Knight et al., 2012). Although the choice 
of antibody, among many other procedural details, needs to be optimized for the 
phospho-ribosome profiling to be applied to reactive astrocytes, my result shows that 
the technique, first of all, can be extended to astrocytes. 
Figure 18: Five phosphorylation sites of ribosome subunit S6 
The five sites of phosphorylation on ribosomal protein S6. The 
phosphorylation of S6 occur in an activity-dependent sequential order i.e. N-
terminal sites (p235/236) are phosphorylated with low, basal activities, while 
the most C-terminal sites (p244/247) are phosphorylated only upon strong 
activities. In this study, antibodies against p240/244 were used. 
3.1.2 pS6 profiling as a potential mean to decipher the molecular identities of 
CNS cells by their stimuli-specific activities 
Based on the initial observation of specific pS6 expression in the superficial dorsal 
horn of the spinal cord following formalin-induced acute pain, I optimized the pS6 
immunoprecipitation protocol and performed the subsequent transcriptomic analysis. 
With my experimental setting, an enrichment observed in the sequencing data could 
mean: (1) the gene is stably expressed in the pS6-positive cells, or (2) the gene is 
induced in the pS6-positive cells by the given stimulation. 
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As shown in Section 2.4.2, of the 11 genes tested by in situ hybridization, only the 
3 induced genes Atf3, Ptg and c-Fos were consistently identified by both in situ 
hybridization and sequencing. Neither could the stably-expressed genes enriched by 
pS6 immunoprecipitation be verified by in situ hybridization (Cdh3, Cdh18, Pcdhb16, 
Meg3 and Ano6), nor could the known dorsal horn specific ‘pain’ genes (Som, Dyn 
and MafA) be enriched by pS6 immunoprecipitation. At this point, I had to conclude 
that, this experimental setting failed to identify stable and robust maker genes for 
spinal cells selectively activated by formalin-induced acute pain. Nevertheless, I 
obtained a molecular profile of all spinal dorsal horn cells, two hours after peripheral 
formalin injection. Therefore, the differentially enriched genes identified in my study 
are those induced by formalin-induced acute pain: mostly immediate early genes, but 
one newly identified pain-induced gene, protein targeting to glycogen, Ptg. 
Several reasons could lead to this result, as illustrated in Fig.19. First of all, I used a 
different p240/244 antibody from the one authors used. I used a monoclonal antibody 
instead of the polyclonal one used by Knight and colleagues. As previously 
mentioned, Knight and colleagues used an antibody against the more C-terminal 
p240/244 sites in order to achieve a greater enrichment. The authors further enhanced 
the selectivity of the antibody by pre-incubating it with a phosphopeptide containing 
the S6 p240 site, thereby obtaining an antibody that recognizes only p244 (Knight et 
al., 2012). I reasoned, that it would not be necessary to pre-incubate the monoclonal 
antibody that I used, since it has high specificity only to a single epitope, which 
reduces the probability of cross reactivity (Lipman et al., 2005). The monoclonal 
antibody, although showed high specificity in immunofluorescent staining, lost its 
selectivity to p240/244 S6 in my immuno-precipitation settings, as shown by the 
western blot in section 2.2.3, and most likely also recognized the more N-terminal 
phosphorylation sites. Nevertheless, my qPCR results suggested that Nk1r, Som and 
FosB are enriched in the ipsilateral (the stimulated side) samples and the 
immunoprecipitation experiment performed reasonably well, therefore I subjected my 
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samples to RNA sequencing. However, the pre-sequencing qPCR results 
unfortunately could not be confirmed by sequencing. There seems to be too little a 
difference in the ipsilateral stimulated and contralateral control samples to identify 
stimuli-specific, stable population markers.  
A further possibility is that the monoclonal pS6 antibody may recognize other 
mRNA bound proteins with a similar epitope or nascent phosphorylation emerging 
from the ribosomes. These cross-reactivities would reduce signal-to-noise ratio, which 
in turn minimizes the ipsilateral-to-contralateral difference. 
I reason that the following changes could improve my pS6 immunoprecipitation: 
(1) more stringent immunoprecipitation conditions to reduce unspecific binding/cross-
reactivities, such as increasing detergent or salt concentration of IP buffers, increasing 
the numbers of washing or prolonging the washing time, 2) optimizing the ratio of 
total protein input to antibody, as the stoichiometry may affect immunoprecipitation 
efficiency and specificity (Marcon et al., 2015), or 3) using possibly a different pS6 
antibody.  
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Figure 19: Possible reasons for the suboptimal phospho-ribosome profiling  
Instead of a specific binding of pS6 antibody to the strongly phosphorylated ribosome (up), the 
antibody may also bind to (i) weakly phosphorylated ribosomes (left) or (ii) other similar phosphor-
moiety in the vicinity (right).
Although I was unable to identify population marker through phospho-ribosome 
profiling, successful phospho-ribosome profiling as a technique has been reported 
once more since its first introduction by Knight and colleagues. In a study by Jiang 
and colleagues, subgroups of specific odorant receptors expressing olfactory neurons 
were successfully identified (Jiang et al., 2015). In this study, the same polyclonal 
anti-p240/244 S6 antibody as in the original protocol was used. The S6 p240-
containing phosphopeptide was not used, as the scientists reported significantly 
reduced mRNA yield after a test pre-incubation and observed relatively low pS6 
background in the olfactory epithelium (Jiang et al., 2015). I speculate this low basal 
level of may be another factor that could have possibly facilitated their experiment, 
and should be taken into consideration in future phospho-ribosome profiling 
experiment design.  
With optimal experimental settings, I believe phospho-ribosome profiling could 
still be a powerful tool to study spinal pain processing. As I could show that pS6 
marks both active neurons and reactive astrocytes, one future application could be to 
obtain separate transcriptomes of these two cell populations. Protocols to isolate 
neurons and different glial cells from CNS tissue, mostly brain, have been previously 
established (Cahoy et al., 2008; Guez-Barber et al., 2012; Saxena et al., 2012; 
Srinivasan et al., 2016). Applying pS6 phospho-ribosome profiling to analyze isolated 
neurons or astrocytes moves forward from the conventional cell type specific 
sequencing and provides an additional activity/function-specific entry point to identify 
cells types responsible for specific functions. 
Nevertheless, the phospho-ribosome profiling led to the discovery that the 
expression of Ptg mRNA is induced by peripheral formalin-induced acute pain. 
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3.2 Ptg induction and the dynamic glycogen level following 
peripheral painful stimuli 
I could show that Ptg co-localizes with the astrocyte marker GFAP. This shows that 
Ptg is induced in spinal astrocytes, which is in line with previous reports that Ptg 
mRNA is expressed in cortical astrocytes (Allaman et al., 2000; Lovatt et al., 2007). 
Ptg regulates glycogen synthesis by mediating the de-phosphorylation of glycogen 
synthase by protein phosphatase 1. Once de-phosphorylated, glycogen synthase 
becomes active and synthesizes glycogen (Brady et al., 1997; Printen et al., 1997; 
Greenberg et al., 2006; Jurczak et al., 2007). A basal expression of Ptg mRNA is 
maintained in cortical astrocytes to meet the metabolic demand under physiological 
conditions (Lovatt et al., 2007), and an elevated expression can be stimulated by the 
neurotransmitter noradrenalin (NA) and the peptide hormone vasoactive intestinal 
peptide (VIP) in cultured astrocytes (Allaman et al., 2000). In my experiments, I could 
show that the induction of astrocytic Ptg mRNA was transient (i.e. induction at 2 
hours and gone by 24 hours) and independent of the type or persistency of pain 
stimulus (formalin/capsaicin/CFA, see section 2.5). This result suggests that it is more 
likely a general pain-triggered induction than specific to certain categories of noxious 
stimulations. Therefore, when I examined the spinal cord 3 days after spared nerve 
injury (SNI), a neuropathic pain model, I could not observe the ipsilateral (operated) 
Ptg induction. Similarly, a recent transcriptomic study using another neuropathic pain 
model, spinal cord injury (SCI), failed to detect the induction of Ptg (Shi et al., 2017). 
The brief, transient induction could potentially explain the absence, as these studies 
were performed at least 1 day after the injury (Chen et al., 2013; Shi et al., 2017). It is 
likely that I would observe an induction of Ptg in the SNI model if I would examine 
the spinal cord 2 hours after operation, but at such short time after surgery, the 
nociceptive input would come from both the surgical wound and the damaged nerves. 
Although the Ptg mRNA induction is transient and independent of the pain model 
used, I found surprising differences in the functional outcome (i.e. the synthesis/
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accumulation of glycogen) (see section 2.6). When comparing the glycogen profiles 
of the pain models studied, an interesting correlation was observed: in formalin/
capsaicin/CFA pain models, although the glycogen elevations in the ipsilateral spinal 
cord, i.e. the stimulated side, were observed around the same time (6 hours after 
stimulation), the extent of glycogen increase and the duration of elevated glycogen 
levels seem to correlate with the severity and persistency of pain. 
The shortest-lasting capsaicin-induced acute pain led to a 1.4 times more ipsilateral 
glycogen, which dropped back to the same levels as the contralateral control side after 
24 hours. Formalin induced a higher, 2-fold glycogen increase in the ipsilateral spinal 
cord, which stayed elevated for 24 hours. The CFA model, which induces longer 
lasting pain (Fehrenbacher et al., 2012), let to elevated glycogen levels for more than 
3 days. And in the case of chronic SNI neuropathic pain, I observed a 2-fold higher 
glycogen levels even 2 weeks after the surgery. 
To briefly recapitulate: (1) a transient Ptg mRNA induction (<1day) in spinal 
astrocytes is triggered by peripheral painful stimuli; (2) glycogen level increases in 
the ipsilateral spinal cord following peripheral painful stimuli; (3) the length and 
magnitude of the elevated ipsilateral glycogen level correlates with the severity and 
persistency of pain. How could this be explained?  
The central terminals of nociceptors release a pool of signaling molecules into 
dorsal horn laminae I and II when activated, including peptide hormone VIP 
(Dickinson & Fleetwood-Walker, 1999). VIP has been reported to stimulate Ptg 
mRNA expression through the cAMP signaling cascade in several studies using in 
cortical astrocyte culture (Sorg & Magistretti, 1992; Allaman et al., 2000; Ruchti et 
al., 2016). While these previous studies were all conducted in vitro, I believe the same 
mechanism may also apply in vivo, i.e. as nociceptors are activated by peripheral 
painful stimuli, they release VIP into superficial dorsal horn, where it is taken up by 
spinal astrocytes to trigger new transcription through cAMP signaling, and Ptg mRNA 
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expression is thereby induced. Following VIP stimulation, Allaman and colleagues 
detected an increase in Ptg mRNA expression in cultured astrocytes as early as 2 
hours after application of VIP, Ptg expression reached a maximum at 4 hours and 
returned to basal level by 24 hours. I found similar Ptg mRNA dynamics in my study, 
although I can not say when the peak was reached as I did not include any time points 
between 2 and 24 hours. 
VIP also affects the glycogen levels in astrocytes. It exerts a biphasic effect on 
glycogen levels via cAMP signaling, i.e. a rapid Ptg-independent glycogen 
mobilization (minutes) and a delayed Ptg-dependent glycogen re-synthesis (hours) to 
replenish the glycogen reserves (Sorg & Magistretti, 1992; Allaman et al., 2000; 
Ruchti et al., 2016). In the study by Sorg and Magistretti, scientists mapped the 
glycogen level of cortical astrocyte cultures following VIP stimulation: (1) the rapid 
glycogen mobilization led to a near depletion 1 hour after application of VIP, and (2) 
as the re-synthesis starts, glycogen level rose back to the basal level 2 hours later, and 
continued to rise until they reached the peak 8 hours after VIP stimulation, and (3) 
returned to basal level 48 hours later. For the later time points, I observed similar 
dynamics in formalin/capsaicin/CFA models (Fig.14): a peak at 6 hours and the 
subsequent return to base line. According to Sorg and Magistretti, the glycogen level 
first dropped then recovered during the first 2 hour. As I did not include a 1 hour time 
point in my time series, I propose two scenarios here: (1) the in vivo condition reflects 
the in vitro observation, and the spinal glycogen level significantly drops 1 hour after 
peripheral painful stimulation or (2) while VIP application virtually affect all the 
astrocytes in culture, in in vivo condition, the number of astrocytes activated by a 
given painful stimuli may be relatively small, and the depletion of their glycogen 
storage may not significantly affect the total spinal dorsal horn glycogen level. As my 
current glycogen measurement does not render cellular resolution, one potential future 
experiment is to apply anti-glycogen antibody to visualize the drop of glycogen levels 
during the early phase  i.e. 0-2 hours after the stimulation.  
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Astrocytic glycogen metabolism is linked with neuronal activity (Magistretti & 
Allaman, 2007). Although astrocytic glycogen was long considered as just an 
emergency energy source, in case of hypoglycemia or ischemia (Obel et al., 2012), 
more and more compelling evidence are suggesting the involvement of astrocytic 
glycogen in neuronal functions under physiological condition (Belanger et al., 2011): 
(1) increased levels of glycogen was found in the sleeping brain, indicating that 
increased neuronal activity in the awake brain consumes glycogen (Magistretti et al., 
1993; Brown, 2004); and (2) decreased glycogen levels were found associated with 
increased neuronal activity, demonstrating the coupling of neuronal activity and 
glycogen mobilization (Swanson et al., 1992; Dienel et al., 2007). As discussed in the 
paragraph above, I hypothesize a decrease in glycogen levels immediately following 
painful stimuli. This decrease would be concurrent with the activation of spinal pain 
neurons, as shown by c-Fos and pS6 stainings (Fig.5), i.e. the nociceptors activate 
spinal neurons as well as the spinal astrocytes. In contrast to previous in vivo brain 
astrocytic glycogen studies (Swanson et al., 1992; Magistretti et al., 1993; Brown, 
2004; Dienel et al., 2007), but in accordance with the in vitro study by Sorg and 
Magistretti, I report a delayed but sustained glycogen re-synthesis. The possible 
reasons for the massive, sustained glycogen re-synthesis will be discussed later in 
light of the possible roles of astrocytic glycogen in pain processing.  
Sorg and Magistretti also reported a correlation between stimulus intensity/
concentration and the magnitude of the Ptg-dependent glycogen re-synthesis. 
Although they did not test if a stronger stimulus would lead to a longer state of 
elevated glycogen, it is a reasonable speculation (Sorg & Magistretti, 1992). This 
partially explains the correlation between the length and magnitude of the elevated 
ipsilateral glycogen level and the severity and persistency of pain I observed. With my 
current dataset, I propose a scenario that (1) within a narrow dynamic range (up to 2 
fold), the stronger the pain is, more astrocytes are activated, and higher the ipsilateral 
glycogen level increases, and (2) once the elevated glycogen level reaches the upper 
limit of 2 fold, the longer the pain persists, the longer the glycogen level remains 
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elevated. This hypothesis is supported by (1) a higher ipsilateral glycogen is reached 6 
hours after the stronger formalin-induced pain than that after the milder capsaicin-
induced pain (2 fold vs 1.4 fold) and (2) formalin/CFA/SNI-pain all resulted in a 2-
fold ipsilateral glycogen increase, but it took longer for the elevated ipsilateral 
glycogen to return to baseline after CFA injection than it did after formalin injection 
(>3 days vs 1 day). Furthermore, it was still 2-fold higher 2 weeks after the chronic 
pain inducing SNI surgery. The 2-fold high glycogen level seems to be the upper limit 
evoked by a single stimulus, as injecting capsaicin to mice already under SNI 
neuropathic pain brought ipsilateral glycogen a further 50% higher i.e. a 3-fold 
increase from contralateral/baseline. Since capsaicin-pain and SNI neuropathic pain 
recruit different nociceptors, and likely different astrocytes as well, the newly 
activated astrocytes by capsaicin-pain contribute to the additional rise. This is also 
consistent with the result that additional painful mechanical stimulus did not further 
increase glycogen levels of mice already with mechanical allodynia. A more complete 
glycogen profile of these pain models would reveal more details about the dynamics 
of glycogen re-synthesis while immunofluorescent staining of the activity marker pS6 
in combination with neuronal marker NeuN could be used to map the exact duration 
of neuronal activities in different pain models. Based on the graded glycogen level 
changes, one additional interesting question would be: is the glycogen change specific 
to painful stimuli? or is it a more general activity triggered process? Testing the 
glycogen levels following innocuous stimuli such as gentle mechanical brushing 
would shed more light in this regard. 
There remains, however, a missing link to account for the different time spans of Ptg 
mRNA and elevated glycogen level. The mRNA is degraded within a day (Fig.13)
(Allaman et al., 2000), while ipsilateral glycogen levels remain elevated as long as the 
pain persists (Fig.14). For the initial phase, the first 24 hour, pain-induced Ptg mRNA 
expression results in new PTG protein synthesis and glycogen synthesis is thereby 
activated. While 2 weeks into SNI neuropathic pain, it is still an open question 
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whether PTG protein is around to mediate the activity of glycogen synthase anymore, 
as there unfortunately lacks a working antibody against PTG. Alternatively, the 
involvement of PTG could be indirectly tested via the visualization of the de-
phosphorylated (active) and the phosphorylated (inactive) forms of glycogen synthase 
by immunofluorescent staining. 
On the other hand, as reduced but still significant amount of glycogen was found in 
the brain of PTG knock-out mice (Turnbull et al., 2011; Turnbull et al., 2014), 
existence of PTG-independent glycogen synthesis pathway(s) has been proposed: (1) 
insulin or glutamate have been reported to mediate glycogen levels in astrocytes 
through PTG-independent mechanism (Swanson et al., 1990; Dringen & Hamprecht, 
1992; Hamai et al., 1999; Allaman et al., 2000), and (2) additional CNS glycogen 
targeting proteins PPP16, PPP1R3F and PPP1R3G (Armstrong et al., 1997; Kelsall et 
al., 2011; Zhang et al., 2014) may sustain normal CNS glycogen synthesis in the 
absence of PTG. One or a combination of these modulators may account for the 
continued glycogen synthesis after the pain-induced Ptg mRNA and the subsequently 
synthesized PTG protein have been degraded or down-regulated and the study of their 
expression in the presence and absence of PTG may reveal more details of the 
complementary metabolic glycogen pathways.  
Before I go on to the roles of astrocytic glycogen in pain processing, I would like to 
mention one more intriguing observation regarding glycogen levels. Eight weeks after 
SNI surgery, the contralateral glycogen levels doubled while the ipsilateral glycogen 
level was still 2-fold elevated. A study by Decosterd and Woolf showed that SNI 
produces only ipsilateral mechanical allodynia but not in the contralateral side 
(Decosterd & Woolf, 2000). However, studies have shown development of bilateral 
mechanical allodynia following unilateral SNI surgery (Swartjes et al., 2011) and 
bilateral increase of the pro-inflammatory cytokine TNF-α and microglia activation 
following other unilateral nerve damages (Hatashita et al., 2008; Jancalek et al., 
2010). Therefore, it is possible that these mice developed contralateral mechanical 
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allodynia, which could be tested in future experiments with the von Frey assay. Both 
increased general metabolic activity and glucose consumption in contralateral spinal 
cord following unilateral forms of nerve injury has been reported (Price et al., 1991; 
Won & Lee, 2015), which are consistent with my observation.  
3.3 The role of astrocytic glycogen in pain processing 
Following peripheral painful stimuli, I showed an induction of astrocytic Ptg mRNA 
and a dynamic pain state-dependent glycogen profile. What does this glycogen do and 
why would the astrocytes synthesize more glycogen during the re-synthesis?  
Two generally accepted hypothesizes of how astrocytic glycogen benefits neurons are 
the inter-cellular transport of glycogen-derived lactate as source of energy and 
glycogen-derived neurotransmitter glutamate (Gibbs et al., 2007; Suzuki et al., 2011; 
Obel et al., 2012; Sickmann et al., 2012; Waitt et al., 2017). 
• Astrocytic glycogen as the source of lactate  
Neurons have been, until recently, believed to obtain their energy through their own 
oxidative metabolism of glucose. Emerging evidences are showing that neurons can 
efficiently utilize lactate and, actually, have a preference for lactate if both glucose 
and lactate are present (Hertz et al., 2007). Upon activation, neurons shift their energy 
source from glucose to lactate (Parsons & Hirasawa, 2010). According to the 
astrocyte-to-neuron lactate shuttle hypothesis (ANLS), glucose is taken up by 
astrocytes and converted to lactate, which is then transported to neurons via 
monocarboxylate transporters (MCT). Lactate then enters the neuronal tricarboxylic 
acid (TCA) cycle to produce ATP (Pellerin & Magistretti, 2012). Moreover, neurons 
have been reported to rely heavily on lactate as their energy source during intense 
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neuronal activity (Pellerin & Magistretti, 2012; Brown & Ransom, 2015). To meet the 
increasing lactate demand during periods of intense stimulation, astrocytic glycogen is 
first broken down by glycogen phosphorylase (GP), which then gets stepwise 
converted to lactate to sustain neuronal activity (Fig.20A) (Brown et al., 2005; Tekkok 
et al., 2005; Falkowska et al., 2015). It is possible that astrocytes synthesize a surplus 
of glycogen in prevention of running out energy supply.  
Figure 20: Current knowledge of glycogen-lactate and glycogen-glutamate pathways  
20A: Glycogen-lactate pathway: astrocytic glycogen is broken down to uridine diphosphate glucose 
(UDP-glucose), which is converted first to glucose 1-phosphate (G-1-P), then glucose 6-phosphate 
(G-6-P), and finally lactate. Astrocytic lactate is then transported to neurons, where it gets converted to 
pyruvate and enters neuronal tricarboxylic acid (TCA) cycle to generate energy.  
20B: Glycogen-glutamate pathway: astrocytic glycogen is first converted stepwise to G-6-P, then to 
pyruvate, which enters astrocytic TCA cycle as both oxaloacetic acid (OAA) and Acetyl CoA. The two 
molecules form first citrate and then α-ketoglutarate (αKG). αKG is transaminated to form glutamate, 
which is subsequently amidated to glutamine. The glutamic is then transported to neurons and 
converted to neurotransmitter glutamate. Direct transport of astrocytic glutamate to neuron has also 
been reported. Adapted from (Falkowska et al., 2015).  
• Astrocytic glycogen as the precursor of glutamate 
Astrocytes are responsible for the replenishment of brain glutamate (Belanger et al., 
2011; Falkowska et al., 2015). In a study by Gibbs and colleagues, it was shown that 
astrocytic glycogen was the preferred precursor of the neurotransmitter glutamate 
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(Gibbs et al., 2007). Astrocytic glycogen is converted to glutamine, which is 
transported to neurons to produce the neurotransmitter glutamate and maintain 
synaptic excitability (Fig.20B). Direct release of glutamate from astrocytes has also 
been reported. Chiang and colleagues proposed that in exaggerated pain states, e.g. 
hyperalgesia and allodynia, reactive astrocytes may release glutamate as glio-
transmitter (Chiang et al., 2012). The glycogen-derived glutamate hypothesis is 
supported by several studies that show significantly suppressed neuronal activity upon 
inhibiting the above-described pathway (Chiang et al., 2007; Chiang et al., 2008; 
Mozrzymas et al., 2011; Sickmann et al., 2012). In other words, if astrocytes run out 
of glycogen, neurons are unable to sustain their activities due to the subsequent 
shortage of glutamine/glutamate. This is another possible explanation why astrocytes 
synthesize extra glycogen following stimulation.  
Measurement of lactate and glycogen levels at different time points after peripheral 
painful stimulus would map out their changes following the stimulation. As 
previously proposed, the glycogen level may show an initial decrease followed by a 
sustained re-synthesis. The levels of lactate and glutamate, the potential end products 
of glycogen, may exhibit an initial  (within the first hour) increase as glycogen is 
being actively mobilized. And in longer term, lactate and glutamate levels may stay 
elevated as long as there are ample glycogen supply.  
3.4 Manipulation of pain through glycogen  
Astrocytic glycogen metabolism correlates with neuronal activity (Cruz & Dienel, 
2002; Magistretti & Allaman, 2007). Therefore, I hypothesized that manipulating 
astrocytic glycogen metabolism would have an impact on pain processing. Indeed, I 
report primary results that (1) increased mechanical and thermal pain sensitivity as 
well as delayed second phase nocifensive behavior in formalin test were observed in 
mice with high spinal glycogen level driven by local PTG over-expression, and (2) 
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suppressed first phase nocifensive behavior in the formalin test were found after 
halting glycogen mobilization by pharmacologically inhibiting the activity of 
glycogen phosphorylase (GP).  
I could show that viral over-expression of PTG led to high spinal glycogen levels 
(Fig.14E), which is consistent with previous in vitro experiments, where a massive 
glycogen increase was observed following PTG over-expression in cultured astrocytes 
(Ruchti et al., 2016) or adipocytes (Greenberg et al., 2003; Greenberg et al., 2006; 
Jurczak et al., 2007). But what is the link between high glycogen levels and the 
observed mechanical and thermal pain hypersensitivity? I hypothesize two possible 
scenarios here: (I) The accumulated glycogen is actively mobilized and contributes 
directly to the hypersensitivity. In the brain, highest glycogen levels are found in areas 
with greatest synaptic densities (Phelps, 1972; Brown & Ransom, 2007), suggesting 
the involvement of glycogen in synaptic transmission. Furthermore, glycogen-derived 
glutamate is believed to promote neuronal activity by maintaining normal synaptic 
excitability, while glycogen-derived lactate acts as fuel for neurons upon intense or 
prolonged stimulation (Gibbs et al., 2007; Suh et al., 2007; Obel et al., 2012; Brown 
& Ransom, 2015; Falkowska et al., 2015; Swanson, 2015). Assuming the accumulated 
glycogen is actively mobilized to glutamine/glutamate and lactate, a reasonable 
speculation is that the excess of glutamate and lactate would prime the neurons to be 
more readily excitable or even hypersensitive. (II) The hypersensitivity is not directly 
linked to glycogen. Glycogen surplus however drives astrocytes into a reactive state, 
and pain hypersensitivity is the result of other glycogen-independent astrocytic 
activity. A recent study by Nam and colleagues reported mechanical and thermal 
hypersensitivity after optogenetic activation of spinal astrocytes (Nam et al., 2016). In 
this study, Nam and colleagues proposed that the release of ATP and proalgesic 
mediators from activated spinal astrocytes are responsible for the increased pain 
response.  
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I propose the following experiments to test the two hypotheses: (1) immuno-
fluorescent stainings of glycogen phosphorylase and astrocyte activity marker e.g. p-
JNK to determine if accumulation of glycogen leads to active glycogen mobilization 
and astrocyte activation; (2) biochemical measurement to determine whether lactate 
and/or glutamate is the end product of the mobilized glycogen; (3) spinal cord 
interstitial fluid analysis to check for changes in ATP and proalgesic mediator levels; 
(4) electrophysiological measurement or immunofluorescent stainings of neuronal 
activity marker c-Fos to test for the excitability/activity of spinal neurons. I found that 
the induction of mechanical allodynia is greater than the induction of thermal 
hyperalgesia similar to observations by Nam and colleagues (Nam et al., 2016). In 
contrast to hypothesis (I) that dorsal horn neurons as a whole are more easily excitable 
upon a surplus of glycogen-derived lactate or glutamate, Nam and colleagues 
speculated that the pain hypersensitivity is the result of the inhibition of GABAergic 
inhibitory interneurons following astrocyte activation. The GABAergic pathway has 
been associated with the development of mechanical allodynia, but not with thermal 
hyperalgesia (Polgar et al., 2003; Nam et al., 2016). Therefore, it is possible that 
thermal sensitivity is less affected following the optogenetic (Nam et al., 2016) or the 
presumed glycogen-driven activation of spinal astrocytes.  
Apart from thermal and mechanical pain, the behavioral response to chemical pain 
was also tested, using the formalin test. In contrast to mechanical or thermal pain, 
formalin chemical pain and the corresponding behavioral response have two phases: 
the first acute phase (0-10min) as the result of nociceptor activation and the second 
tonic phase (15-50min) coming from the sensitization of spinal dorsal horn neurons 
(Tjolsen et al., 1992; Abbadie et al., 1997; McNamara et al., 2007). The PTG over-
expression mice showed similar first and second peaks as the control mice. However, 
I found a delay of the second phase. This would suggest that the acute phase, i.e. the 
activation of nociceptors as well as the dorsal horn neurons they project to, is not 
affected by the high spinal glycogen level. This would contradict hypothesis (I), in 
which dorsal horn neurons as a whole become more excitable with the surplus of 
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glycogen-derived lactate and glutamate, but may fit hypothesis (II). As suggested by 
Nam and colleagues, the activated astrocytes act to inhibit certain subgroups of 
inhibitory neurons, leading to disinhibition of excitatory spinal interneurons. Although 
the inhibitory pathway involved in formalin chemical pain is yet not clear, I speculate 
that similar as in the case of thermal pain, it could be less affected by the inhibition of 
inhibitory neurons following astrocyte activation. I used 3xFLAG-tagged PTG in my 
over-expression experiments, but if I substitute the FLAG with a fluorescent protein, 
the affected interneurons which are next to the astrocytes could potentially be 
characterized by slice electrophysiological measurements combined with single-cell 
qPCR.  
The second phase on the other hand, though of same magnitude and duration as in 
control mice, is delayed. The second phase involves sensitization/plasticity of dorsal 
horn neurons. Previous studies have shown that memory formation, which also 
involves neuronal plasticity, is critically dependent on the transfer of astrocytic 
glycogen-derived lactate to neurons (Suzuki et al., 2011; Boury-Jamot et al., 2016). 
Does a readily accessible rich reservoir of glycogen facilitate this process? My result 
suggests otherwise, high glycogen level, instead, seems to delay the second phase. I 
suggest a serial titrated viral over-expressions to confirm a dose-dependent correlation 
between the delay and the level of glycogen elevation. Intrathecal administration of 
exogenous lactate or glutamate could potentially reveal which end product(s) of 
glycogen mobilization may be contributing to the delay. 
In addition to increasing spinal glycogen level by PTG over-expression, I pharma-
cologically blocked spinal glycogen mobilization by intrathecally injecting 1,4-
dideoxy-1,4-imino-D-arabinitol (DAB). DAB is a potent inhibitor of glycogen 
phosphorylase (GP), the first enzyme in the glycogenolysis process which breaks 
glycogen down to smaller UDP-glucose molecules. Subsequent formalin test showed 
a significantly suppressed first phase and an unchanged second phase. The suppressed 
first phase supports the hypothesis that astrocytic glycogen plays an essential role in 
neuronal activity. The behavior response is significantly suppressed, but not 
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abolished, indicating that (1) a certain level of neuronal activity is sustained, and (2) 
there exists additional, probably less efficient energy supply than astrocytic glycogen-
derived lactate. C-Fos stainings could be used to examine whether there are fewer 
neurons activated or the neurons fire weaker. A study by Dienel and colleagues 
showed an compensatory increase of glucose utilization upon the inhibition of GP 
activity during normal brain activity (Dienel et al., 2007). As glycogen is a better 
source of energy than glucose for sudden, intense activity (Berg et al., 2002), I 
speculate that the compensatory glucose  metabolism does not suffice the large energy 
demand following formalin-induced acute pain, therefore the nocifensive behavior is 
attenuated. In addition, I suggest that the nocifensive response would be abolished if 
astrocytic metabolism is inhibited by an astrocyte-specific TCA cycle blocker 
fluorocitrate, which achieves its specificity by inhibiting the astrocyte-specific 
utilization of acetate (Hassel et al., 1992; Meller et al., 1994; Swanson & Graham, 
1994).  
As the second phase, which involves neuronal plasticity, is critically dependent on 
the astrocytic glycogen-derived lactate, as the above-mentioned studies suggested 
(Suzuki et al., 2011; Boury-Jamot et al., 2016), I would predict a significantly 
suppressed second phase by DAB as well. Strikingly, the second phase was found 
unchanged in the DAB injected mice and the controls. As the role of DAB as GP 
inhibitor has long been established, I think the most plausible explanation here is that 
the intrathecally injected DAB has been diffused and/or degraded. As glycogen 
mobilization resumes, the nocifensive response is also recovered. In previous in vivo 
studies, DAB was administrated directly into the tissue, such as the intra-
hippocampus injections employed by Matsui and colleagues as well as by Suzuki and 
colleagues, which showed an effective time of 1 hour (Suzuki et al., 2011; Matsui et 
al., 2017). It is a reasonable speculation that the circulation of cerebral spinal fluid 
expedited the diffusion of DAB, shortening its effective time in my experimental 
setting. A spinal cord cassette could be implanted to facilitate an intra-spinal DAB 
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injection, which should provide longer effective time to cover the second phase of 
formalin test and shed more light on the impact of glycogen on spinal pain processing.  
3.5 Summary and perspectives 
  
In this study, I identified protein targeting to glycogen (Ptg) as a pain-induced gene. 
The Ptg mRNA induction in spinal astrocytes is transient, but glycogen levels were 
elevated from 24h to several weeks depending on the different pain models. There 
seems to be a correlation between the magnitude and duration of elevated glycogen 
levels and the persistency of pain. Over-expression of PTG in spinal astrocytes 
significantly increased local glycogen levels and led to the development of both 
mechanical and thermal hypersensitivity. Inhibition of spinal glycogenolysis, on the 
other hand, suppressed the pain behavior during the first phase of formalin test.  
The mechanism of how exactly glycogen is involved in spinal pain processing remain 
unresolved: whether the glycogen is broken down to lactate for energy or to glutamate 
for signaling. To understand glycogen metabolism in pain, both acute and chronic, 
would be one direction for future studies.  
The involvement of astrocytes in (chronic) pain is attracting more and more attention. 
However, changes in metabolic states, either of astrocytes or neurons, have not been 
addressed in the context of pain. Ptg and glycogen open up a new angle to investigate 
the role of astrocytic and neuronal metabolism in pain processing. While the adverse 
side effects of current pain-suppressing drugs come from the fact that they act on our 
nervous system, understanding the metabolic changes in (chronic) pain may  provide 
an alternative direction of for pain medication discovery. One potential hurdle in 
interfering with metabolic activities is the difficulty to achieve specificity. Many 
substances used to interfere with one metabolic activity often interact with other 
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pathways. DAB, a widely used glycogen phosphorylase inhibitor employed in this 
study, has reported interaction also with glycogen synthase (Walls et al., 2008). 
Specific inhibitor of PTG and/or careful maneuver of the metabolic state of chronic 
pain patients may be one promising therapeutic possibility. 
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4. Material and methods  
4.1 Mice 
Housing: Animal housing and experiments were conducted following the animal 
welfare and use guidelines (Regierungspräsidium Karlsruhe, Germany). C57BL/6J 
mice were bred at the animal facility of University of Heidelberg (Interfakultäre 
Biomedizinische Forschungseinrichtung, IBF) or purchased from Javier Labs. Both 
male and female mice were used for the experiments. Prior to experiments, mice were 
given 24-72h to habituate in the lab.  
Pain models: 
Formalin pain model: 36.5% formaldehyde solution (Sigma, F8775) was diluted with 
0.9% NaCl sterile saline (B.Braun, 190/150936) to a 5% solution shortly before 
injection. Formalin-induced pain was induced by intraplantar injection of 15µL of the 
5% formaldehyde solution into the hind paw of the mouse, under shallow anesthesia 
by isoflurane.   
Capsaicin pain model: 0.6% capsaicin/DMSO solution (obtained from Rohini Kuner 
lab) was diluted with sterile saline to a 0.06% suspension shortly before injection. 
Capsaicin-induced pain was induced by intraplantar injection of 20µL of the 0.06% 
capsaicin solution into the hind paw of the mouse, under shallow anesthesia by 
isoflurane. 
CFA pain model: 10µL of Complete Freund’s Adjuvant (Sigma, F5881) was injected 
into the hind paw while mouse was under shallow anesthesia by isoflurane to induce 
the inflammatory pain.  
SNI pain model: The SNI surgery was performed by severing two of the three 
branches of the sciatic nerve (the tibial nerve and the common peroneal nerve). The 
mice were under isoflurane anesthesia during the surgery and were let to recover for 
at lease one week before subjected to any measurement/experiments.  
4.2 Immunofluorescence Staining 
Sample preparation: At different time points after intraplantar injection of formalin, 
the mice were perfused first with PBS (Sigma, D8537) then 4% Paraformaldehyde/
PBS (Sigma, 16005). After perfusion, the mice were dissected to collect the lumbar 
spinal cord. The spinal cord piece was incubated in 20% sucrose/PBS (Sigma S0389) 
overnight at 4ºC with gentle shaking for the purpose of cryoprotection and embedded 
in OCT (Tissue-Tek® O.C.T. Compound, Sakura, 4583). The sample was sectioned to 
12µM on a Leica CM3050S Research Cryostat and collected on glass slides 
(HistoBond, 0810001). The sections were stored in -80ºC until further experiment. 
Staining: Immunofluorescent staining was performed on spinal cord sections collected 
as above described. The sections were first let to warm up to room temperature and 
then washed in PBST (0.1% TritonX(Merck, 108603)/PBS) for 2 times, 5 minutes 
each. Blocking was performed with 1% goat serum in PBST for 1 hour at room 
temperature. The sections were incubated with primary antibody (pS6 Cell Signaling 
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2215, 1:2000) in blocking buffer overnight at 4ºC. After washing in PBST 3 times, 10 
minutes each, secondary antibody (1:1000 in blocking buffer) was applied to the 
sections and let to incubate at room temperature for 1 hour. The sections were 
mounted in Immu-Mount (Thermo Scientific, 9990402) after another washing in 
PBST (3 times, 10 minutes each) and preserved in 4ºC.  
4.3 Wholemount immunofluorescent staining 
Sample preparation: Mice were sacrificed 2 hours after intraplantar formalin injection 
and immediately perfused as previously described. After perfusion, the spinal cord 
was dissected out and subject to 4 hours of post-fixation in 4% Paraformaldehyde/
PBS at 4ºC with gentle rotation. The tissue piece was then washed in PBS for 10 
minutes and put into Dent’s Bleach (10% H2O2(Merck, 107209), 13.3% 
DMSO(Sigma, D2438) and 53.3% Methanol(Honeywell, 32213)) for 24 hours at 4ºC 
with gentle rotation. After bleaching, the tissue piece was subject to dehydration with 
methanol at room temperature for 5 times, 2 minutes each. The sample was then fixed 
in Dent’s Fix (20% DMSO, 80% Methanol) for 24 hours at 4ºC with general rotation. 
The tissue was stored in Dent’s Fix at 4ºC until use. 
Staining: The processed tissue was rinsed with PBS 3 times, 20 minutes each to wash 
off the Dent’s Fix and then incubated with primary antibody in blocking buffer (same 
as in section 4.2) at 4ºC with gentle rotation for 5 days. After primary antibody 
incubation, the tissue sample was washed with PBS at room temperature for 6 times, 
30 minutes each. Secondary antibody was diluted in blocking solution (as in section 
4.3) and the tissue piece was let to incubate for 2 days at room temperature with 
gentle rotation. After the incubation, the tissue piece was again washed with PBS for 6 
times, 30 minutes each at room temperature.  
Clearing: After staining, the spinal cord piece was dehydrated and cleared before 
imaging. First dehydration was performed by incubating the tissue piece in 
50%methanol/PBS for 5 minutes at room temperature, followed by 20 minutes of 
incubation in 100% methanol, changing the solution twice during the incubation. 
After dehydration, the piece was cleared in BABB (1 part benzyl alcohol(Sigma, 
108006) and 2 parts benzyl benzoate(Sigma, B6630)) for 5 minutes and stored in 
BABB till imaging.  
4.4 Western blot  
Sample preparation 
spinal cord tissue: two hours after intraplantar injection of formalin, the mice were 
sacrificed and the lumbar spinal cord was quickly dissected in ice cold PBS. The 
whole spinal cord or the dorsal horn laminae I-III spinal cord was collected and snap 
froze immediately. The spinal cord tissue piece was kept in -80ºC until 
homogenization. Homogenization buffer was freshly prepared (NP40-RIPA buffer: 
50mM pH 7.4 Tris (Roth, 4855), 1% NP40(Sigma, I8896), 0.5% sodium 
deoxycholate(Sigma, D6750), 150mM NaCl(Bernd Kraft, 04160.5600), 1mM 
EDTA(Roth, X986.2), 0.1% SDS(Roth, 2326), 1x cOmplete™ Protease Inhibitor 
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Cocktail(Roche, 11697498001), 1x PhosSTOP phosphatase inhibitor tablet(Roche, 
04906845001)).  
HEK293 cell culture: after harvest, the cell culture medium was removed and the cells 
were collected in cold PBS. Excessive PBS was removed after pelleting cells by 
centrifugation at 1000rpm, 10 minutes. The cells were re-suspended and lysed in 2x 
Laemmli buffer, supplemented with 2-mercaptoethanol. The cell lysis was incubated 
at 95ºC for 5 minutes and let to cool down on ice. The lysate was directly loaded on to 
the western blot gel or stored in -20ºC until use.  
Blotting: Depending on the number of wells, 10-20µL tissue or cell lysates were 
loaded into each well (Life Technologies, NP0321). The gel was let run for 1/1.5 hour 
at 180/120V. The transfer to PVDF membranes (Roche, 03010040001) was performed 
at 30V for 50 minutes. The transfer chamber was placed in ice during the transfer. 
Protein visualization: After the proteins were transferred to the nitrocellulose 
membrane, blocking with 5% milk/PBST (milk powder, Roth, T145.2, 0.1% Tween, 
Roth, 9127, in PBS) was performed for 1 hour at room temperature with gentle 
rotation. After blocking, the membrane was briefly rinsed with PBST and placed in 
primary antibody (pS6 Cell Signaling 5364 1:10000, β-ACTIN 1:5000, GFP Nacalai 
Tesque 04404-84, 1:1500, PTG Abnova D03P 1:1000, FLAG Sigma F1804 1:3000, in 
3%BSA(Roth, T844.4)/PBST) at 4ºC overnight. The next day, the membrane was 
washed 3 times, 10 minutes each with PBST at room temperature and subject to 
secondary antibody incubation (1:1000, in 3%BSA/PBST) for 1 hour at room 
temperature. The membranes were washed again 3 times, 10 minutes each with PBST 
before developing. GE Amersham ECL Prime Western Blotting Detection Reagent 
(RPN2232) was used for detection.  
4.5 Immunoprecipitation/Ribosome capture 
Sample preparation: For sequencing experiments, 5 mice were pooled for each 
sample. Three samples of each conditions were prepared. Immunoprecipitation was 
performed based on the protocol developed by Knight and colleagues (Knight et al., 
2012). The mice were sacrificed 2 hours after formalin injection and quickly dissected 
in ice cold freshly prepared buffer B (1xHBSS(Life Technologies, 14185-045), 4mM 
NaHCO3(AppliChem, 131638.1211), 2.5mM pH7.4 HEPES(Roth, 9105.4), 35mM 
Glucose(Merck, 08337), 100 µg/ml cycloheximide(Sigma, C7698)). The tissue was 
snap froze and kept in -80ºC. The tissues were kept frozen until homogenization.  
Homogenization: Tissue was resuspended in 1350µL freshly prepared buffer C 
(10mM pH7.4 HEPES, 150 mM KCl(Sigma, P9541), 5 mM MgCl2(Sigma, M2670), 
1x PhosSTOP phosphatase inhibitor tablet, 1x cOmplete™ Protease Inhibitor 
Cocktail, 2mM DTT(Sigma, 10197777), 100U/ml RNasin(Promega N2515), 100 µg/
ml cycloheximide) and homogenized at 4ºC. The homogenates were centrifuged at 
2000g for 10 minutes at 4ºC and the supernatants (~1mL) were transferred to new 
tubes on ice. 90µL 10% NP40 and 90µL 1,2-diheptanoyl-sn-glycero-3-
phosphocholine (DHPC, Avanti Polar Lipids, 850306, 100mg/0.69mL, freshly 
prepared) were added to each tube. The new mix was centrifuged at 17000g for 10 
minutes at 4ºC and the supernatant was collected in a clean tube. A small aliquot of 
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the supernatant was taken for western blot (“Ly”) and the rest were used for 
immunoprecipitation.  
Antibody coating: 3µg of pS6 Cell Signaling 5364 antibody and 50µL Protein A 
Dynabeads (Invitrogen 1001D) were used for each immunoprecipitation. Antibody 
was incubated with Dynabeads in 1mL buffer A (0.1% TritonX/PBS) for 10 minutes at 
room temperature with gentle rotation. The coated beads were equilibrated in buffer C 
till immunoprecipitation.  
Immunoprecipitation: Immunoprecipitation was performed by applying the 
supernatant to pS6 coated protein A Dynabeads and rotated at 4ºC for 10 minutes. 
After immunoprecipitation, the liquid were collected for western blot (“SN”). The 
beads were washed for four times in 500µL buffer D (10mM pH7.4 HEPES, 350mM 
KCl, 5mM MgCl2, 2mM DTT, 1% NP40, 100 U/ml RNasin, and 100 µg/ml 
cycloheximide). During the third wash, the beads were transferred to a new tube and 
let to incubate at room temperature for 10 minutes. Phospho-ribosomes were eluted 
with 350µL RLT (or 50µL 2x laemmli for western blot, “IP”). The eluates were 
immediately processed to RNA extraction for test qPCR or deep sequencing.  
4.6 qPCR 
RNA extraction: RNA extraction was performed using RNAeasy micro kit (QIAGEN, 
74004), following the manufacturer’s instruction. The elution volume was 10µL. The 
RNA was reverse transcribed using SuperScript III Reverse Transcriptase (Thermo 
Fisher, 18080044) and Oligod(T)23VN (NEB, S1327) following the manufacturer’s 
instruction for SuperScript First-Strand Synthesis System (Thermo Fisher).  
Primer design: qPCR primers were designed using the commercial software OLIGO 
(version 7). Primers used:  
qPCR: qPCR were performed using the FastStart Essential DNA Green Master 
(Roche, 06402712001) and Roche LightCycler® 96 Instrument, following the 
manufacturer's instruction.  
4.7 RNA sequencing  
RNA extraction: RNA were extracted from IP eluates as described in section 4.6. The 
obtained RNA were snap frozen and kept at -80ºC till use.  
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Calb2-Fw: AATGAACTGGACGCCCTC; Dyn-Fw: AAGCTCTTGGAACCCGTCCTG; 
Calb2-Rv: GGCCAAGGACATGACACTCT; Dyn-Rv: TTTCCGTTGCCAAAGCTGCTG; 
Som-Fw: GAGGACCTGCGACTAGACTGA; NK1R-Fw: ACAACCCCATCATCTACTGCT; 
Som-Rv: CAGGACAGCATCTTCCTTGC; NK1R-Rv: TTCCAGCCCCTCATAATCACC; 
Gad67-Fw: TCTTCCAGCCAGACAAGCAG; FosB-Fw: GGCCTAGAAGACCCCGAGAA; 
Gad67-RV: AGCCAGAACTTGAAGATGTCC; FosB-Rv: TTTCCGCCTGAAGTCGATCTGT
Reverse transcription and amplification: cDNA synthesis and amplification was 
performed following the SMART-Seq2 protocol described by Picelli and colleagues 
(Picelli et al., 2014) and optimized by EMBL Genecore. 2µL of RNA was used as the 
starting material and a 18 cycles of amplification was performed. 
Quality control: The amplified cDNA from the step above was subject to 
concentration measurement by Qubit dsDNA HS Assay kit (Thermo Fisher, Q32854) 
and then quality check on a bioanalyzer (Agilent High Sensitivity DNA Kit, 
5067-4626). A small aliquot the amplified cDNA was used for test qPCR testing while 
the remaining were kept at -20ºC until further process. qPCR primers used:  
Library preparation, barcoding and sequencing: Library preparation and barcoding 
were performed following the standard protocol of EMBL Genecore (Nextera XT 
DNA Library Preparation Kit, FC-131-1096 and Nextera XT Index Kit v2 Set A, 
FC-131-2001), using 125pg amplified cDNA as input. The sequencing was performed 
by EMBL Genecore on Illumina MiSeq platform.  
Data analysis: The sequencing reads were aligned by EMBL Genecore to mouse 
genome Mm10. FastQC was used for quality check and the differential expression 
analysis was performed with R following the Bioconductor RNA-Seq workflow 
developed by Love and colleagues (Love et al., 2015). The following packages were 
used during the data analysis: DESeq2, Rsamtools, GenomicFeatures, 
TxDb.Mmusculus.UCSC.mm10.ensGene, GenomicAlignments, AnnotationDbi, 
org.Mm.eg.db.  
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Atf3-Fw: AGGAAGAGCCAAAGATAACCAC Rem2-Fw: TCTCCCGGAAAGACACTCCA
Atf3-Rv: TCCCACAATGCAGATGCCT Rem2-Rv: AGGCATGTTCCGAGTACCAA
Ppp1r3c-Fw: GGTGACTCATCTTTCTGCCACA Actb-Fw: ATCAAGATCATTGCTCCTCC
Ppp1r3c-Rv: CAAGACAAAATTAGGCACGAGA Actb-Rv: GACTCATCGTACTCCTGCTT
Pcdhb16-Fw: ACTGAATACACCCGACATAGCAA Klf15-Fw: CTTTGTGCCTTCCTGCCAG
Pcdhb16-Rv: CCAGTAGAGGCCAAATAAAGCAA Klf15-Rv: AAAACACTTCTTCCCCAGCAA
Lck-Fw: ACATGTGTCTTATACCTGTGGAGC MVK-Fw: TGAGACCACCCGACACACC
Lck-Rv: AGAGACACGCATCAATCGCAGA MVK-Rv: CCATCTCAGAAGACCCCACA
Ano6-Fw: GTCCTGAACATGCTCCCTC Sez6l-Fw: AGCCTTTGAAGCCAGCTC
Ano6-Rv: AAGCACAGAAAAGGAGCTCT Sez6l-Rv: TACGGTTCCTGAAGCTACCCAT
Meg3-Fw: TCCCCTTGAGTAGAGAGACCC MMD-Fw: GACATAACTTCGCTACATGCCTT
Meg3-Rv: CAGTGAAGACACAACAGCCTT MMD-Rv: TCGCCATGATTCAGAAAGCTC
Gab1-Fw: CTGGCCTGCTCTTACTCC
Gab1-Rv: CGCACACTAACTGAAGCACT
4.8 In situ hybridization  
Sample preparation: Spinal cord were dissected 2 hours after intraplantar formalin 
injection in ice cold PBS and immediately embedded into OCT and frozen using dry 
ice/isopropanol. 20µm sections were prepared using Leica CM3050S cryostat and 
stored at -80 °C until staining. 
Probe design and synthesis: In situ hybridization probes were designed using 
commercial software OLIGO (version 7). Primers used: 
Cdh3-fw: gacGTCGACCAAGTGCTGAACATCACTGACA 
Cdh3-rv: gacGCGGCCGCCATAGTCCTGGTCCTCTTCACC 
Cdh18-fw: gacCTCGAGGCCACCACTCTTTTCTATGCC 
Cdh18-rv: gacGCGGCCGCCATTCTCTCGCACATCCTCC 
Pcdhb16-fw: gacCTCGAGAAGTGCGATTGAAAGAACACC 
Pcdhb16-rv: gacGCGGCCGCTAGTGCCACCCTTCTGCAT 
Meg3-fw: gacCTCGAGATTGCTGTAGACAAAGCCACCT 
Meg3-rv: gacGCGGCCGCCCTTTCCTGATCACGCCAT 
Ano6 (pool of 3 used) 
fw1: gacCTCGAGTGCCTCCTTGAACTGACCAC  
rv1: gacGCGGCCGCACCAGCCTTTCCCATAACCC 
fw2: gacCTCGAGCCTAGCGAGCGTTACCTCC 
rv2: gacGCGGCCGCTAGTGCCACCCTTCTGCAT 
fw3: gacCTCGAGTGCCTCCTTGAACTGACCAC 
rv3: gacGCGGCCGCCTGCGTGAGGTATTTCTCCC 
Atf3-fw: gacCTCGAGCTCCTTTTCCACCCCACACC 
Atf3-rv: gacGCGGCCGCGCTCTTCCTGCCCTGTCAC 
Ppp1r3c-fw: gacGTCGACAAGAACTTTGTCTGCCTCGAGA 
Ppp1r3c-rv: gacGCGGCCGCTACCACAGCGTTCCATCACC 
Probe sequences were amplified from spinal cord cDNA, molecularly cloned into 
pBlueScript plasmids and bacterially amplified. DIG-labeled in situ probes were 
subsequently synthesized (POD: Roche, 11207733910, AP: Roche, 11093274910). c-
Fos, Som, Dyn and MafA probes were produced and provided by Dr. Hong Wang and 
Dr. Hagen Wende.  
AP/fluorescent in situ hybridization: stainings were performed using the protocols 
(AP and fluorescent) optimized in the Jan Siemens lab and described in the recent 
publication by Song and colleagues (Song et al., 2016). All probes were used at 1:100 
dilution.  
Immunofluorescent-in situ hybridization double staining: single color fluorescent in 
situ hybridization was performed following the same protocol as above, after the 
single color fluorescent in situ hybridization was completed, the sections were subject 
to antibody immunofluorescent staining (pS6 Cell Signaling 2215 1:1000, GFAP Cell 
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Signaling 3670 1:500, NeuN Cell Signaling D4G40 1:2000, IBA1 Wako, 019-19741, 
1:500) using the protocol described in 4.2.   
4.9 Glycogen assay 
Sample preparation: Spinal cord dorsal horn was dissected in ice cold PBS and 
immediately snap froze. The samples were kept in -80ºC till measurement.  
Glycogen measurement: Spinal cord tissue was sonicated in 120µL ddH2O and 
incubated at 99ºC for 10 minutes at 350rpm to inactivate enzymes. After heat 
inactivation, the homogenates were centrifuged at 18000g for 10 minutes at 4ºC. The 
supernatants (100-110µL) were collected to clean tubes. Two aliquots of the collected 
supernatants (35µL each) were mixed with 15µL hydrolysis buffer, with (sample) and 
without  (negative control) 1µL hydrolysis enzyme, respectively. The remaining steps 
were performed following the manufacturer’s instruction. Glycogen standard curve 
was prepared in every experiment to counter the kit to kit variances. 25µL of the 
remaining supernatants were used for protein measurement (Pierce™ BCA Protein 
Assay Kit, 23225). After glycogen and protein measurements, the glycogen level of 
each sample were calculated by extracting that of the corresponding negative control, 
multiplied by the dilution factor (35µL/120µL) and normalized to the protein 
contents.  
4.10 Viral-mediated PTG over-expression  
Cloning of pAAV-GFAP-3xFLAG-PTG and pAAV-GFAP-Venus: Dr. Anna Hertle 
provided the GFAP multi-cloning-site AAV plasmid. 3xFLAG and PTG sequences 
were PCR amplified from a 3xFlag containing plasmid from Charlotte Rostock and 
spinal cord cDNA respectively, and cloned into GFAP plasmid using In-Fusion® HD 
Cloning Kit (Clonetech, 121416). Venus sequence was digested from a Venus 
containing plasmid from Dr. Hagen Wende and ligated into the GFAP AAV plasmid. 
The plasmids were bacterial amplified and sequenced to confirm the correct inserts.  
PTG test expression: After the AAV plasmids were correctly produced, the 3xFLAG-
PTG insert was digested out and ligated into pcDNA. HEK293 cells were transfected 
with pcDNA-3xFLAG-PTG and pBlueScript control plasmids. 48 hours after 
transfection, the cells were collected for western blot analysis. The western blot 
detection of PTG and FLAG was performed as described in section 4.4.  
Virus production: The AAV viruses were produced by Karin Meyer in Rohini Kuner’s 
lab using AAV serotype 1 and 2. The cleaned supernatants were collected and kept at 
-80ºC until injection.  
Virus test on astrocyte culture: astrocyte culture was prepared by Dr. Anna Hertle. 14 
days after infection with PTG and Venus viruses respectively, the cultured cells were 
fixed with 4% Paraformaldehyde/PBS. The cultures were incubated with GFAP 
antibody (Cell Signaling 3670 1:500) to visualize the astrocytes and with FLAG 
(Sigma F1804 1:500) antibody to mark the PTG over-expression. Venus over-
expression was detected by its own fluorescence.  
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Spinal cord over-expression: Spinal cord virus injection was performed by Dr. 
Manuela Simonetti. For each mouse, bilateral injection of 1µL of virus mixed with 
equal amount of mannitol was perform at dorsal horns of lumbar section L2. The mice 
were let to recover for 3 weeks before behavioral testings. 
4.11 von Frey and Hargreaves tests  
Mice were habituated for 3 days before the testing. Both von Frey and Hargreaves 
tests were performed following standard protocols of the Interdisciplinary 
Neurobehavioral Core at University of Heidelberg. In short, a filament set of 0.07g, 
0.14g, 0.4g, 0.6g, and 1.0g were used in the von Frey measurement. 5 measurements 
were performed for each filament and the response is calculated as the percentage 
(number of response/5). For Hargreaves test, the lamp was set to 40Lux.  
4.12 DAB-mediated glycogen mobilization inhibition 
1,4-dideoxy-1,4-imino-D-Arabinitol (DAB, Cayman Chemicals, 20939) was 
dissolved in sterile PBS and 100pmol working dilution was prepared. 10µL DAB/PBS 
or PBS control solution was intrathecally injected by Dr. Manuela Simonetti 15 
minutes before intraplantar formalin injection. The mice were video recorded for 55 
minutes for formalin test behavioral quantification.  
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5. Appendix  
A1 Characterization of MafA knock-out mouse line 
Introduction  
The Maf family acts as transcriptional factors (Wende et al., 2012). Studies have 
revealed spinal cord neuronal subtypes identified by different members of the Maf 
family, such as MafA, c-Maf, and Maf-B (Bourane et al., 2009). c-Maf is distinctively 
expressed at lamina III (Fig.A1-A, down), whereas the expression of MafA expands 
also to the more superficial laminae I and II (Fig.A1-A, up) where nociceptive 
afferents come in, indicating an additional role of MafA in nociception. In this side 
project, I performed initial molecular and behavioral characterizations a MafA knock-
out mouse line produced by Dr. Hagen Wende, in the context of pain. 
Results 
In order to determine whether the MafA-expressing spinal cord neurons are excitatory 
or inhibitory, I first performed double fluorescent in situ hybridization of MafA with 
excitatory (vGlut2 and vGlut3) and inhibitory (Gad65 and Gad67) neuron markers. 
Quantification of the stainings is shown in Fig.A1-B. The majority of MafA-
expressing neurons are excitatory.  
As I speculated a potential involvement of MafA in pain processing for its superficial 
dorsal horn expression, I performed von Frey test to test the mechanical pain 
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threshold (Fig.A1-C). The knock-out mice showed no difference in mechanical pain 
thresholds as the heterozygote controls.  
I further tested if a phenotype would emerge when the mice are under chronic pain. 
I performed SNI surgery to induce neuropathic pain and measured the mechanical 
pain threshold before and after the surgery (Fig.A1-D). The MafA knock-out mice 
showed an interesting phenotype, i.e. under neuropathic pain, the MafA knock-out 
mice developed hypersensitivity in both ipsilateral (operated) and contralateral (un-
operated) paw. Whereas the control mice only developed hypersensitivity in the 
operated paw.  
Discussion 
Nociceptive inputs from the peripheral are processed at spinal cord superficial dorsal 
horn (Basbaum et al., 2009). The laminae I and II expression of MafA points to its 
potential involvement in pain processing. In this side project, I found that under 
chronic neuropathic pain, MafA knock-out mice developed hypersensitivity for 
mechanical pain in the un-operated control paw. Previous studies have reported 
development of mirror pain in the contralateral paw in certain knock-out mouse lines 
following SNI surgery (Racz et al., 2008; La Porta et al., 2013). Racz and colleagues 
also observed an enhanced activity of contralateral spinal dorsal horn astrocytes as the 
pain developed in the contralateral paw (Racz et al., 2008). I hypothesize a potential 
inhibitory role of MafA-expressing neurons in the cross-talking of spinal cord pain 
circuits, i.e. MafA-expressing neurons act to prevent the activation of the pain 
processing neurons on the contralateral side. Further thorough investigations would be 
needed to elaborate the exact connections and mechanisms of the observed phenotype. 
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Figure A1: Molecular and behavioral characterization of MafA knock-out mouse 
A: Up: MafA (in situ hybridization) expression spread from laminae I to III while Down: c-Maf (in situ 
hybridization) showed specific lamina III expression.  
B: Quantification of MafA-expressing spinal neurons. 92% of MafA-possitive neurons co-express 
vGlut2 and 5% express vGlut3.  
C: von Frey test of MafA knock-out mice and heterozygote controls. MafA knock-out mice did not 
show altered mechanical sensitivity (N=8 each).  
D: von Frey test of MafA knock-out mice and heterozygote controls after SNI surgery. MafA knock-out 
mice developed mechanical hypersensitivity in both operated paw and the un-operated paw; while 
heterozygous control mice only developed hypersensitivity in the operated side. 
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